<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:09:34Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10481756" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10481756</identifier>
        <datestamp>2023-09-07</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="add16154" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Addiction</journal-id>
              <journal-id journal-id-type="iso-abbrev">Addiction</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1360-0443</journal-id>
              <journal-id journal-id-type="publisher-id">ADD</journal-id>
              <journal-title-group>
                <journal-title>Addiction (Abingdon, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0965-2140</issn>
              <issn pub-type="epub">1360-0443</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10481756</article-id>
              <article-id pub-id-type="pmcid">PMC10481756</article-id>
              <article-id pub-id-type="pmc-uid">10481756</article-id>
              <article-id pub-id-type="pmid">36750134</article-id>
              <article-id pub-id-type="pmid">36750134</article-id>
              <article-id pub-id-type="doi">10.1111/add.16154</article-id>
              <article-id pub-id-type="publisher-id">ADD16154</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Report</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Reports</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment</article-title>
                <alt-title alt-title-type="right-running-head">CANNABIS EFFECTS IN ADOLESCENTS AND ADULTS</alt-title>
                <alt-title alt-title-type="left-running-head">Lawn et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="add16154-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lawn</surname>
                    <given-names>Will</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0143-2724</contrib-id>
                  <xref rid="add16154-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="add16154-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>will.lawn@kcl.ac.uk</email>
                  </address>
                </contrib>
                <contrib id="add16154-cr-0002" contrib-type="author">
                  <name>
                    <surname>Trinci</surname>
                    <given-names>Katie</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0003" contrib-type="author">
                  <name>
                    <surname>Mokrysz</surname>
                    <given-names>Claire</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1970-8530</contrib-id>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0004" contrib-type="author">
                  <name>
                    <surname>Borissova</surname>
                    <given-names>Anna</given-names>
                  </name>
                  <xref rid="add16154-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="add16154-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0005" contrib-type="author">
                  <name>
                    <surname>Ofori</surname>
                    <given-names>Shelan</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0006" contrib-type="author">
                  <name>
                    <surname>Petrilli</surname>
                    <given-names>Kat</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9801-1442</contrib-id>
                  <xref rid="add16154-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0007" contrib-type="author">
                  <name>
                    <surname>Bloomfield</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="add16154-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="add16154-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0008" contrib-type="author">
                  <name>
                    <surname>Haniff</surname>
                    <given-names>Zarah R.</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0009" contrib-type="author">
                  <name>
                    <surname>Hall</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0010" contrib-type="author">
                  <name>
                    <surname>Fernandez‐Vinson</surname>
                    <given-names>Natalia</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0011" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Simiao</given-names>
                  </name>
                  <xref rid="add16154-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0012" contrib-type="author">
                  <name>
                    <surname>Englund</surname>
                    <given-names>Amir</given-names>
                  </name>
                  <xref rid="add16154-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="add16154-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0013" contrib-type="author">
                  <name>
                    <surname>Chesney</surname>
                    <given-names>Edward</given-names>
                  </name>
                  <xref rid="add16154-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="add16154-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0014" contrib-type="author">
                  <name>
                    <surname>Wall</surname>
                    <given-names>Matthew B.</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="add16154-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0015" contrib-type="author">
                  <name>
                    <surname>Freeman</surname>
                    <given-names>Tom P.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5667-507X</contrib-id>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="add16154-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="add16154-cr-0016" contrib-type="author">
                  <name>
                    <surname>Curran</surname>
                    <given-names>H. Valerie</given-names>
                  </name>
                  <xref rid="add16154-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="add16154-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychology, Institute of Psychiatry Psychology and Neuroscience</named-content>
                <institution>King's College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Addictions, Institute of Psychiatry Psychology and Neuroscience</named-content>
                <institution>King's College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Clinical Psychopharmacology Unit, Clinical Educational and Health Psychology</named-content>
                <institution>University College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neuroimaging, Institute of Psychiatry Psychology and Neuroscience</named-content>
                <institution>King's College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">NIHR University College London Hospitals Biomedical Research Centre</named-content>
                <institution>University College Hospital</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Addiction and Mental Health Group (AIM), Department of Psychology</named-content>
                <institution>University of Bath</institution>
                <city>Bath</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry</named-content>
                <institution>University College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychosis Studies, Institute of Psychiatry Psychology and Neuroscience</named-content>
                <institution>King's College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="add16154-aff-0009" content-type="private-address">
                <label>
                  <sup>9</sup>
                </label>
                <institution>Invicro London</institution>
                <named-content content-type="street">Burlington Danes Building, Hammersmith Hospital, Du Cane Road</named-content>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Will Lawn, Department of Psychology, Institute of Psychology Psychiatry and Neuroscience, King's College London, Guy's Campus, Great Maze Pond, SE1 1UL London, UK.<break/>
Email: <email>will.lawn@kcl.ac.uk</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <volume>118</volume>
              <issue seq="110">7</issue>
              <issue-id pub-id-type="doi">10.1111/add.v118.7</issue-id>
              <fpage>1282</fpage>
              <lpage>1294</lpage>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 Society for the Study of Addiction-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">Addiction</italic> published by John Wiley &amp; Sons Ltd on behalf of Society for the Study of Addiction.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ADD-118-1282.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="add16154-sec-0001">
                  <title>Background and Aims</title>
                  <p>Long‐term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects of cannabis in adolescents. We aimed to (i) compare the acute effects of cannabis in adolescent and adult cannabis users and (ii) determine if cannabidiol (CBD) acutely modulates the effects of delta‐9‐tetrahydocannabinol (THC).</p>
                </sec>
                <sec id="add16154-sec-0002">
                  <title>Design</title>
                  <p>Randomised, double‐blind, placebo‐controlled, crossover experiment. The experiment was registered on <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (NCT04851392).</p>
                </sec>
                <sec id="add16154-sec-0003">
                  <title>Setting</title>
                  <p>Laboratory in London, United Kingdom.</p>
                </sec>
                <sec id="add16154-sec-0004">
                  <title>Participants</title>
                  <p>Twenty‐four adolescents (12 women, 16‐ to 17‐year‐olds) and 24 adults (12 women, 26‐ to 29‐year‐olds) who used cannabis 0.5–3 days/week and were matched on cannabis use frequency (mean = 1.5 days/week).</p>
                </sec>
                <sec id="add16154-sec-0005">
                  <title>Intervention</title>
                  <p>We administered three weight‐adjusted vaporised cannabis flower preparations: ‘THC’ (8 mg THC for 75 kg person); ‘THC + CBD’ (8 mg THC and 24 mg CBD for 75 kg person); and ‘PLA’ (matched placebo).</p>
                </sec>
                <sec id="add16154-sec-0006">
                  <title>Measurements</title>
                  <p>Primary outcomes were (i) subjective ‘feel drug effect’; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory).</p>
                </sec>
                <sec id="add16154-sec-0007">
                  <title>Findings</title>
                  <p>Compared with ‘PLA’, ‘THC’ and ‘THC + CBD’ significantly (<italic toggle="yes">P</italic> &lt; 0.001) increased ‘feel drug effect’ (mean difference [MD] = 6.3, 95% CI = 5.3–7.2; MD = 6.8, 95% CI = 6.0–7.7), impaired verbal episodic memory (MD = –2.7, 95% CI = −4.1 to −1.4; MD = −2.9, 95% CI = −4.1 to −1.7) and increased psychotomimetic effects (MD = 7.8, 95% CI = 2.8–12.7; MD = 10.8, 95% CI = 6.2–15.4). There was no evidence that adolescents differed from adults in their responses to cannabis (interaction <italic toggle="yes">P</italic> ≥ 0.4). Bayesian analyses supported equivalent effects of cannabis in adolescents and adults (Bayes factor [BF<sub>01</sub>] &gt;3). There was no evidence that CBD significantly modulated the acute effects of THC.</p>
                </sec>
                <sec id="add16154-sec-0008">
                  <title>Conclusions</title>
                  <p>Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, verbal memory‐impairing or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta‐9‐tetrahydocannabinol.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="add16154-kwd-0002">adolescence</kwd>
                <kwd id="add16154-kwd-0003">cannabis</kwd>
                <kwd id="add16154-kwd-0004">CBD</kwd>
                <kwd id="add16154-kwd-0006">cognition</kwd>
                <kwd id="add16154-kwd-0007">memory</kwd>
                <kwd id="add16154-kwd-0008">psychosis</kwd>
                <kwd id="add16154-kwd-0010">subjective drug effects</kwd>
                <kwd id="add16154-kwd-0011">THC</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Medical Research Council
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000265</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/P012728/1</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="3"/>
                <page-count count="13"/>
                <word-count count="10721"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>July 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.3 mode:remove_FC converted:06.09.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="add16154-cit-9001"><string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Trinci</surname><given-names>K</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Borissova</surname><given-names>A</given-names></string-name>, <string-name><surname>Ofori</surname><given-names>S</given-names></string-name>, <string-name><surname>Petrilli</surname><given-names>K</given-names></string-name>, et al. <article-title>The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment</article-title>. <source>Addiction</source>. <year>2023</year>;<volume>118</volume>(<issue>7</issue>):<fpage>1282</fpage>–<lpage>1294</lpage>. <pub-id pub-id-type="doi">10.1111/add.16154</pub-id>
<pub-id pub-id-type="pmid">36750134</pub-id></mixed-citation>
              </p>
              <fn-group id="add16154-ntgp-0001">
                <fn id="add16154-note-0001">
                  <p><bold>Funding information</bold> This study was funded by the Medical Research Council (MR/P012728/1 to H.V.C. and T.P.F.).</p>
                </fn>
                <fn id="add16154-note-0002">
                  <p>The first two authors contributed equally to this article.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="add16154-body-0001">
            <sec id="add16154-sec-0009">
              <title>INTRODUCTION</title>
              <p>Cannabis is the most commonly used internationally controlled drug in the world and is particularly popular among adolescents. Between 15% and 20% of English 15‐year‐olds [<xref rid="add16154-bib-0001" ref-type="bibr">1</xref>, <xref rid="add16154-bib-0002" ref-type="bibr">2</xref>] and 28% of American 15‐ to 16‐year‐olds [<xref rid="add16154-bib-0003" ref-type="bibr">3</xref>] report using cannabis in the last year. Globally, roughly half of those who try cannabis do so are aged 18.5 years or younger [<xref rid="add16154-bib-0004" ref-type="bibr">4</xref>]. Adolescents are approximately three times more likely than adults to develop cannabis addiction in the years immediately after initiating cannabis use [<xref rid="add16154-bib-0005" ref-type="bibr">5</xref>, <xref rid="add16154-bib-0006" ref-type="bibr">6</xref>, <xref rid="add16154-bib-0007" ref-type="bibr">7</xref>]. Meanwhile, cannabis laws are rapidly evolving across the world [<xref rid="add16154-bib-0008" ref-type="bibr">8</xref>], which is likely to have profound impacts on young people [<xref rid="add16154-bib-0009" ref-type="bibr">9</xref>, <xref rid="add16154-bib-0010" ref-type="bibr">10</xref>, <xref rid="add16154-bib-0011" ref-type="bibr">11</xref>]. Accordingly, there is an urgent need to understand the acute psychopharmacological effects of cannabis in teenagers.</p>
              <p>Adolescence is a period during which important biological, neural, psychological, social and personal changes occur [<xref rid="add16154-bib-0012" ref-type="bibr">12</xref>, <xref rid="add16154-bib-0013" ref-type="bibr">13</xref>, <xref rid="add16154-bib-0014" ref-type="bibr">14</xref>, <xref rid="add16154-bib-0015" ref-type="bibr">15</xref>]. Crucially, the endocannabinoid (eCB) system continues to develop, with changing levels of cannabinoid receptors and endocannabinoids [<xref rid="add16154-bib-0016" ref-type="bibr">16</xref>, <xref rid="add16154-bib-0017" ref-type="bibr">17</xref>]. It is also a time when mental health problems typically begin to emerge [<xref rid="add16154-bib-0018" ref-type="bibr">18</xref>], with 14 years being the average age of onset of mental illness [<xref rid="add16154-bib-0019" ref-type="bibr">19</xref>]. In epidemiological studies, long‐term cannabis use in adolescence has been associated with an increased likelihood of psychosis [<xref rid="add16154-bib-0020" ref-type="bibr">20</xref>], mood disorders [<xref rid="add16154-bib-0021" ref-type="bibr">21</xref>] and poorer cognitive function and educational achievement [<xref rid="add16154-bib-0022" ref-type="bibr">22</xref>]. Therefore, there is concern that the potential harms of cannabis use may be accentuated in adolescents who are at a critical neurodevelopmental stage [<xref rid="add16154-bib-0023" ref-type="bibr">23</xref>]. However, the acute effects of cannabis intoxication in adolescents have rarely been studied in controlled settings.</p>
              <p>Acutely, cannabis reliably produces an array of transient and dose‐dependent effects including intoxication, euphoria, memory impairment, psychotomimetic effects, anxiogenic effects, attention deficits and tachycardia [<xref rid="add16154-bib-0024" ref-type="bibr">24</xref>, <xref rid="add16154-bib-0025" ref-type="bibr">25</xref>, <xref rid="add16154-bib-0026" ref-type="bibr">26</xref>, <xref rid="add16154-bib-0027" ref-type="bibr">27</xref>]. Notably, there is wide interindividual variation [<xref rid="add16154-bib-0027" ref-type="bibr">27</xref>]. The major psychoactive effects of cannabis arise from delta‐9‐tetrahydrocannabinol (THC), which is a partial cannabinoid‐1 receptor (CB1R) agonist. Cannabidiol (CBD), which is the second most abundant phytocannabinoid [<xref rid="add16154-bib-0028" ref-type="bibr">28</xref>], has a complex pharmacology [<xref rid="add16154-bib-0029" ref-type="bibr">29</xref>], including inhibition of anandamide metabolism [<xref rid="add16154-bib-0027" ref-type="bibr">27</xref>], agonism of the serotonin‐1A receptor [<xref rid="add16154-bib-0030" ref-type="bibr">30</xref>] and negative allosteric modulation of CB1 receptors [<xref rid="add16154-bib-0031" ref-type="bibr">31</xref>]. CBD may moderate some of the acute effects of THC [<xref rid="add16154-bib-0032" ref-type="bibr">32</xref>]; however, findings have been inconsistent. CBD has sometimes been shown to attenuate the short‐term harmful effects of THC [<xref rid="add16154-bib-0033" ref-type="bibr">33</xref>] and sometimes not [<xref rid="add16154-bib-0034" ref-type="bibr">34</xref>], which may be related to CBD dose, route of administration and user characteristics. High‐dose oral (600 mg) and intravenous (5 mg) CBD attenuated the psychotomimetic effects [<xref rid="add16154-bib-0035" ref-type="bibr">35</xref>, <xref rid="add16154-bib-0036" ref-type="bibr">36</xref>] and episodic memory impairing effects of THC [<xref rid="add16154-bib-0036" ref-type="bibr">36</xref>], but 8 mg of vaporised CBD did not [<xref rid="add16154-bib-0034" ref-type="bibr">34</xref>, <xref rid="add16154-bib-0037" ref-type="bibr">37</xref>]. The moderating influence of CBD co‐administration on the acute effects of cannabis in adolescents is unknown.</p>
              <p>Despite the pervasiveness of adolescent cannabis use, only one controlled human experiment has compared the acute effects of cannabis in adolescents under the age of 18 years and adults [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>]. Participants were 20 adolescent males (16–17 years old) and 20 adult males (24–28 years old) who used cannabis an average of 2.4 and 1.8 days/week, respectively. Participants inhaled vaporised cannabis (8 mg THC for a 75 kg person) or placebo cannabis. Notably, adolescents reported less intense subjective effects, fewer psychotomimetic symptoms and exhibited less episodic memory impairment than adults. However, in this study, adolescents used cannabis significantly more frequently than adults and weighed less than adults, so received a lower absolute dose of THC.</p>
              <p>More recently, one placebo‐controlled study compared the impact of oral THC (7.5 and 15 mg) in young people 18–20 years old and adults 30–40 years old with limited cannabis experience [<xref rid="add16154-bib-0039" ref-type="bibr">39</xref>]. They found similar responses on all subjective effects, cardiovascular measures, working memory and response inhibition; however, the 18‐ to 20‐year‐olds experienced stronger electroencephalography and psychomotor changes compared with adults [<xref rid="add16154-bib-0039" ref-type="bibr">39</xref>]. One observational, ecological momentary assessment study examined the associations between age and subjective response in 15‐ to 24‐year‐old frequent cannabis users [<xref rid="add16154-bib-0040" ref-type="bibr">40</xref>]. Contrastingly, they reported that being older was associated with diminished self‐reported stimulatory response and subjective ‘high’. Moreover, non‐human animal research has found mixed results; acute cannabinoid agonists elicited stronger anxiogenic effects in adults [<xref rid="add16154-bib-0041" ref-type="bibr">41</xref>], but provoked greater impairments in learning in adolescents [<xref rid="add16154-bib-0042" ref-type="bibr">42</xref>].</p>
              <p>In sum, no studies have investigated the combined effects of CBD and THC in adolescents, in whom the impact may be different from adults. Only one controlled experiment to date has compared the acute effects of cannabis in human adolescents under the age of 18 years with adults [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>], which had the following limitations: (i) no female participants; (ii) the adolescents used cannabis more frequently than the adults; (iii) the modulatory impact of CBD was not studied; and (iv) no pharmacokinetic data were collected.</p>
              <p>To address these limitations, we tested equal numbers of female and male participants, included a combined THC and CBD (‘THC + CBD’) condition as well as THC‐only (‘THC’) and placebo (‘PLA’) conditions, carefully matched cannabis use frequency between the groups and collected pharmacokinetic data. In the largest study of its kind, we aimed to replicate the adolescent versus adult difference in acute effects of cannabis and to explore the modulatory impact of CBD co‐administration in these age groups.</p>
              <p>First, we hypothesised that, across age‐group, there would be a main effect of drug, such that (i) subjective ‘feel drug effect’, (ii) verbal episodic memory impairment, and (iii) psychotomimetic effects, would be greater on ‘THC’ and ‘THC + CBD’ than placebo. Second, we hypothesised that CBD in ‘THC + CBD’ would reduce the (i) verbal episodic memory impairing, and (ii) psychotomimetic effects, relative to ‘THC’, but (iii) subjective ‘feel drug effect’ would be similar on ‘THC’ and ‘THC + CBD’. Third, we hypothesised there would be an interaction between age‐group and drug, such that the expected difference between the ‘THC’ and ‘PLA’ conditions on measures (i)–(iii) would be greater for adults than for adolescents.</p>
            </sec>
            <sec sec-type="methods" id="add16154-sec-0010">
              <title>METHODS</title>
              <sec id="add16154-sec-0011">
                <title>Study design and participants</title>
                <p>The experiment was registered on <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (NCT04851392), and the protocol was uploaded to the Open Science Framework (OSF) [<xref rid="add16154-bib-0043" ref-type="bibr">43</xref>].</p>
                <p>We conducted a randomised, double‐blind, placebo‐controlled, crossover experiment on the acute effects of cannabis in adolescents and adults. The experiment had a between‐subjects factor of age group (adolescent and adult) and a within‐subjects factor of drug (‘THC’, ‘THC + CBD’, ‘PLA’).</p>
                <p>This was a single‐centre study conducted at University College London and Invicro (Hammersmith Hospital, United Kingdom [UK]). We recruited healthy participants from the community in London, UK. The study received full ethical approval from UCL Ethics Committee (project code: 5929/005). This study was registered on <ext-link xlink:href="http://Clinical.Trials.gov" ext-link-type="uri">Clinical.Trials.gov</ext-link> (NCT04851392). All participants provided written, informed consent and provided verbal ongoing consent at the beginning of each study session.</p>
                <p>We continued recruitment until we reached our target sample size of 48 completed participants, comprising 24 adolescents (50% female; 16–17 years old) and 24 adults (50% female; 26–29 years old). Participants who did not complete all sessions were replaced. Key inclusion criteria were self‐reported use of cannabis 0.5, 1, 2 or 3 days/week; healthy or overweight body mass index (BMI); and right‐handed. Key exclusion criteria were The Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM‐5) severe cannabis use disorder; currently receiving treatment for a mental health disorder; history of personal or familial psychosis; pregnant or breast‐feeding; use of any illicit drug (apart from cannabis) more than 2 days per month; nicotine dependence as defined by a Heaviness of Smoking score &gt;1 [<xref rid="add16154-bib-0044" ref-type="bibr">44</xref>]; currently taking a psychotropic medication that interacts with cannabis or directly affects outcome variables; magnetic resonance imaging (MRI) contraindications; and if an adult, cannabis use at a frequency ≥1 day/week before turning 18 years old. For full eligibility criteria, see Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S1</xref>. Cannabis use frequency (days per week) was purposefully matched between the adolescents and adults.</p>
              </sec>
              <sec id="add16154-sec-0012">
                <title>Randomisation and blinding</title>
                <p>There were six drug orders. Each order was used with eight participants (one sixth of total sample), to ensure that drug order was balanced. Drug order was balanced within age‐group and gender. Within these groups, participants were randomly allocated to drug order using a blocked randomisation sequence. All experimental researchers and participants were blinded to treatment allocation. At the end of each session, participants were asked to guess which drug they thought they had received that day.</p>
              </sec>
              <sec id="add16154-sec-0013">
                <title>Procedures</title>
                <p>Participants were screened online and via telephone. Potentially eligible participants attended an in‐person (pre‐coronavirus disease [COVID]) or virtual (post‐COVID) baseline session. In‐person eligibility criteria were confirmed at either the in‐person baseline or first drug administration session.</p>
                <p>Eligible participants then completed three drug administration sessions. At the start of each session, recent alcohol and illicit drug use were checked to ensure abstinence via an alcohol breathalyser, a saliva drugs test and self‐report. Female participants completed a urine pregnancy test. Drug administration sessions lasted 5–6 h in total. Participants completed assessments before and after cannabis inhalation (Table <xref rid="add16154-tbl-0001" ref-type="table">1</xref> and Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S1</xref>). MRI data, other neurocognitive task data and detailed pharmacokinetic and physiological data will be reported elsewhere, as these results are beyond the scope of this manuscript.</p>
                <table-wrap position="float" id="add16154-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Schedule of experiment events for drug administration sessions to the nearest 5 min, relative to the start of drug administration (T‐inh)</p>
                  </caption>
                  <table frame="hsides" rules="cols">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Time (min)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Timepoint</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Event</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">−70</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">In‐person eligibility checks: alcohol breathalyser, saliva drugs test, pregnancy test, recent drug use, TLFB, physical checks, BMI</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">−40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Cannulation, radiographer checks</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">−5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Blood sample, BP/HR, VAS</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T‐inh</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Drug administration</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+20</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Blood sample, BP/HR, VAS</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Prose recall (immediate)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Blood sample, BP/HR, VAS</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+45</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">MRI scan</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+120</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">BP/HR, subjective effects</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+125</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Prose recall (delayed)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+125</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Psychotomimetic states inventory</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+140</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Neurocognitive tasks</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+160</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">T5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Blood sample, BP/HR, VAS</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+180</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">PANSS interview</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">+210</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">Drug guess, subjective ratings, sobriety tests, discharge</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="add16154-ntgp-0002">
                    <fn id="add16154-note-0003">
                      <p><italic toggle="yes">Note</italic>: MRI data, neurocognitive task data and pharmacokinetic and physiological data at T3, T4 and T5 will be reported elsewhere.</p>
                    </fn>
                    <fn id="add16154-note-0004">
                      <p>Abbreviations: BMI = body mass index; BP = blood pressure; HR = heart rate; MRI = magnetic resonance imaging; PANSS = Positive and Negative Syndrome Scale; PSI = Psychotomimetic States Inventory; T‐inh = the time that drug inhalation started; TLFB = timeline follow‐back; VAS = visual analogue scale.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Dried medical cannabis flower was procured from Bedrocan (<ext-link xlink:href="https://bedrocan.com/" ext-link-type="uri">https://bedrocan.com/</ext-link>) in the Netherlands and imported under H.V.C.'s UK Home Office licence. Cannabis types used were ‘Bedrocan’ (20.2% THC; 0.1% CBD), ‘Bedrolite’ (0.4% THC; 8.5% CBD) and ‘Bedrobinol Placebo’. Dose was weight‐adjusted [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>]: The ‘THC’ condition contained 0.107 mg/kg THC (8 mg THC for a 75 kg person); the ‘THC + CBD’ condition contained 0.107 mg/kg THC and 0.320 mg/kg CBD (8 mg THC and 24 mg CBD for a 75 kg person); and the ‘PLA’ condition contained no THC or CBD and was matched in appearance and smell to the other conditions. This dose of THC corresponds to approximately one quarter of a typical ‘joint’ [<xref rid="add16154-bib-0045" ref-type="bibr">45</xref>, <xref rid="add16154-bib-0046" ref-type="bibr">46</xref>], or 1.6 standard THC units [<xref rid="add16154-bib-0047" ref-type="bibr">47</xref>, <xref rid="add16154-bib-0048" ref-type="bibr">48</xref>]. The total weight of cannabis flower material was kept constant across the conditions through the addition of placebo cannabis. Cannabis was vaporised into a ‘balloon’ using a Volcano Medic Vaporiser (Storz and Bickel), and participants inhaled the contents of the balloon according to a standardised, timed procedure. The minimum washout period was 3 days (72 h) between drug sessions [<xref rid="add16154-bib-0049" ref-type="bibr">49</xref>]; the elimination half‐life of THC is 21.5 h [<xref rid="add16154-bib-0050" ref-type="bibr">50</xref>, <xref rid="add16154-bib-0051" ref-type="bibr">51</xref>], giving adequate time for THC elimination.</p>
              </sec>
              <sec id="add16154-sec-0014">
                <title>Outcomes</title>
                <p>The registered primary outcome variables were (i) strength of the subjective drug effect, as measured by self‐reported ‘feel drug effect’ [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>] 20 min after the start of cannabis inhalation (i.e. almost immediately after inhalation completion) (T2); (ii) verbal episodic memory, as measured by delayed prose recall [<xref rid="add16154-bib-0052" ref-type="bibr">52</xref>] 2 h after the start of cannabis inhalation (T4); and (iii) psychotomimetic effect, as measured by the total Psychotomimetic States Inventory (PSI) score [<xref rid="add16154-bib-0053" ref-type="bibr">53</xref>] 2 h after the start of cannabis inhalation (T4).</p>
                <p>The subjective ‘feel drug effect’ visual analogue scale (VAS) is a single‐item scale rated from 0 (not at all) to 10 (extremely). The prose recall task requires participants to listen to a 30‐s story presented via headphones, immediately write down as much as they can remember, and then again write down as much as they can remember 100 min later. The PSI is a 48‐item self‐report questionnaire assessing psychotic‐like symptoms.</p>
                <p>Secondary variables were (i) psychotomimetic effect, as measured by the Positive and Negative Syndrome Scale (PANSS) positive and negative subscales [<xref rid="add16154-bib-0054" ref-type="bibr">54</xref>] 3 h after the start of cannabis inhalation, when the participant is sober and reflects on their experiences; (ii) psychotomimetic effect measured via PSI subscales, including delusory thinking, perceptual distortion, cognitive disorganisation, anhedonia, mania and paranoia, 2 h after the start of drug inhalation (T4); (iii) subjective effects of ‘anxious’, ‘paranoid’, ‘want cannabis’, ‘feel drug effect’, ‘like drug effect’, ‘dislike drug effect’ and ‘happy’ measured via 10‐point visual analogue scales (VAS; 0 not at all to 10 extremely) at 5 min pre‐cannabis (T1), 20 min (T2), 30 min (T3), 120 min (T4) and 160 min (T5) after the start of cannabis inhalation; (iv) THC and CBD plasma levels 20 min after the start of cannabis inhalation (T2); and (v) heart rate 20 min after the start of cannabis inhalation (T2). See <xref rid="add16154-supitem-0001" ref-type="supplementary-material">Supporting Information</xref> for a detailed description of all measures.</p>
              </sec>
              <sec id="add16154-sec-0015">
                <title>Statistical analyses</title>
                <p>The study was powered to replicate our previous finding that adolescents experienced a weaker psychotomimetic effect of cannabis than adults [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>]. We found an effect size of Cohen's f = 0.33 for the age‐group (adolescent, adult) by drug (THC, placebo) interaction on total PSI score. To obtain 80% power in our current experiment to replicate this 2 × 2 interactive result, with ɑ = 0.05, number of groups = 2, number of repeated measures = 2 (‘THC’ and ‘PLA’) and a conservative repeated‐measures correlation = 0.2, 32 participants were required. We, therefore, recruited 48 participants to complete the study and account for winner's curse (+50%) [<xref rid="add16154-bib-0055" ref-type="bibr">55</xref>]. For other analyses, with our set <italic toggle="yes">n</italic> = 48, three repeated measures, ɑ = 0.05, we had an estimated 80% power to detect a within‐subjects main effect (drug) and a within‐between interaction (age group by drug) with effect sizes of Cohen's f ≥0.24.</p>
                <p>The analysis followed our OSF analysis plan [<xref rid="add16154-bib-0056" ref-type="bibr">56</xref>], which was published before data collection was completed and before data were unblinded. A per‐protocol analysis was used; only participants who completed all three experimental sessions were included. Data were first pre‐processed, and assumptions were examined (see <xref rid="add16154-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). For each of the three primary outcome variables, a 2 × 3 mixed ANOVA with a between‐subjects factor of age group (adolescent, adult) and a within‐subjects factor of drug (‘PLA’, ‘THC’, ‘THC + CBD’) was conducted. The main effect of drug (‘PLA’ vs ‘THC’ vs ‘THC + CBD’) and the interaction between drug and age group were first examined. Where significant main effects or interactions were detected (α cut‐off of 0.05), these were explored with <italic toggle="yes">post hoc</italic> pairwise Bonferroni‐corrected <italic toggle="yes">t</italic> tests, which compared all conditions against one another. We corrected for multiple comparisons within each primary outcome variable, but not across all primary outcome variables. If a Greenhouse–Geisser correction was implemented, we report uncorrected degrees of freedom. Where data violated assumptions for parametric analyses, we proceeded with parametric tests, but non‐parametric analyses were also conducted to support findings. We re‐ran all primary analyses with drug order included as a between‐subjects covariate to test whether drug order altered the pattern of results.</p>
                <p><italic toggle="yes">Post hoc</italic> Bayesian <italic toggle="yes">t</italic> tests were conducted to support null differences. Bayes factors (BF<sub>01</sub>) &gt;3 were interpreted as evidence in favour of no difference. For primary outcome variables, differences between ‘THC’ and ‘PLA’ (‘THC minus PLA’) were calculated and underwent Bayesian independent <italic toggle="yes">t</italic> tests to test for equivalence in response to cannabis in adolescents and adults. Across age‐group, Bayesian paired <italic toggle="yes">t</italic> tests were used to test for equivalence in ‘THC + CBD’ and ‘THC’ conditions. All analyses were conducted using SPSS (Version 25).</p>
                <p>Secondary outcome variables were primarily analysed via two‐way or three‐way mixed ANOVAs similar to the ANOVAs described above. Three‐way ANOVAs included a within‐subject factor of time. For subjective effect VASs, time had levels: T1/T2 to T5, and separately area‐under‐the‐curve and peak effects were analysed. For prose recall, time had levels: immediate and delayed. For THC and CBD plasma results at T2, mixed effects models were performed to account for eight missing data points out of 144. Positive and negative PANSS scores were analysed using mixed ANOVAs and supported with generalised estimating equations models and χ<sup>2</sup> and McNemar's tests. See <xref rid="add16154-supitem-0001" ref-type="supplementary-material">Supporting Information</xref> for full details.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="add16154-sec-0016">
              <title>RESULTS</title>
              <p>Data collection started on 11 March 2019 and concluded on 16 June 2021 when 48 participants (<italic toggle="yes">n</italic> = 24 adolescents, 50% female and <italic toggle="yes">n</italic> = 24 adults, 50% female) had completed all three drug administration sessions, as planned (Consolidated Standards of Reporting Trials diagram; Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S3</xref>). Data collection was suspended from March 2020 until November 2020 because of the COVID‐19 pandemic, after which the experiment resumed in a safe way according to government and local regulations.</p>
              <p>After weight adjustment by participants' actual weight, adolescents received a mean THC dose of 6.8 mg (SD = 0.9; range = 5.4–8.7 mg), and adults received a mean THC dose of 7.4 mg (SD = 1.4; range = 5.4–10.7 mg) on both ‘THC’ and ‘THC + CBD’ conditions. On ‘THC + CBD’ adolescents received a mean CBD dose of 20.3 mg (SD = 2.6; range = 16.3–26.1 mg), and adults received a mean CBD dose of 22.2 mg (SD = 4.3; range = 16.3–32.2 mg) of CBD. These differences were not statistically significant (THC: <italic toggle="yes">t</italic>(45) = 1.760, <italic toggle="yes">P</italic> = 0.085; CBD: <italic toggle="yes">t</italic>(45) = 1.762, <italic toggle="yes">P</italic> = 0.085).</p>
              <p>For a summary of participant characteristics, see Table <xref rid="add16154-tbl-0002" ref-type="table">2</xref> (for full details see Tables <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S4–S8</xref>). Adolescents had a mean age of 17.17 years (SD = 0.43), and adults had a mean age of 27.77 years (SD = 1.04). Cannabis use frequency was purposefully matched between adolescents (1.41 days/week, SD = 0.77) and adults (1.45 days/week, SD = 0.77). Adolescents and adults had similar socio‐economic status, ethnicity, problematic alcohol consumption levels, cigarette/roll‐up use and other illicit drug use. However, adolescents had higher depression, anxiety and impulsiveness scores and adults had higher verbal IQ and alcohol use frequency.</p>
              <table-wrap position="float" id="add16154-tbl-0002" content-type="TABLE">
                <label>TABLE 2</label>
                <caption>
                  <p>Summary of participants' baseline sociodemographic characteristics and drug use</p>
                </caption>
                <table frame="hsides" rules="cols">
                  <col align="left" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Adolescents (<italic toggle="no">n</italic> = 24)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Adults (<italic toggle="no">n</italic> = 24)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Both (<italic toggle="no">n</italic> = 48)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Gender</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">12 (50.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">12 (50.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">24 (50.0%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">12 (50.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">12 (50.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">24 (50.0%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age (years)<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">17.17 (0.43) [16.50–17.92]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">27.77 (1.04) [26.33–29.58]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">22.47 (5.41) [16.50–29.58]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">21.89 (2.81) [17.36–26.67]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">23.18 (2.73) [19.40–27.80]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">22.53 (2.82) [17.36–27.80]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Ethnicity</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">17 (70.8%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">18 (75.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">35 (72.9%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mixed</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (16.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (4.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (10.4%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asian</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (4.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (12.5%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (8.3%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (8.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (4.2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (4.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (2.1%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prefer not to say</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (4.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (2.1%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">SES</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mother's education below undergraduate degree</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8 (33.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8 (33.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">16 (33.3%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mother's education undergraduate degree or above</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">16 (66.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">16 (66.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">32 (66.7%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BDI<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">10.38 (8.55) [0.00–28.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5.29 (6.45) [0.00–22.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7.83 (7.92) [0.00–28.00]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">s‐UPPS‐P<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">48.17 (7.51) [34.00–61.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">42.75 (8.87) [30.00–64.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">45.46 (8.58) [30.00–64.00]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">CUDIT‐R<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">10.17 (3.14) [5.00–16.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7.21 (3.31) [3.00–15.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8.69 (3.53) [3.00–16.00]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">AUDIT<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5.88 (5.39) [0.00–21.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7.71 (4.59) [1.00–18.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6.79 (5.04) [0.00–21.00]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Cannabis use frequency (days/week) measured at baseline</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.41 (0.77) [0.25–3.50]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.45 (0.77) [0.25–2.75]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.43 (0.76) [0.25–3.50]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Cannabis use frequency (days/week) measured at screening</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0.5</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (16.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (16.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8 (16.7%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7 (29.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (20.8%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">12 (25.0%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8 (33.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7 (29.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">15 (31.3%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (20.8%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">8 (33.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">13 (27.1%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Estimated amount of cannabis used on day of use (grams)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.81 (0.56) [0.25–2.50]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.50 (0.52) [0.10–2.00] {n = 23}</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.66 (0.55) [0.10–2.50] {n = 47}</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age of first cannabis use (years)<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">14.55 (1.03) [11.92–16.08]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">18.17 (2.62) [14.00–24.42]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">16.36 (2.69) [11.92–24.42]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Lifetime days of cannabis use<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">153.67 (89.97) [11.00–418.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">544.29 (630.94) [136.00–3120.00]</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">349.13 (487.63) [11.00–3127.00]</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Weekly alcohol use<xref rid="add16154-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">19 (79.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6 (25.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">25 (52.1%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (20.8%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">18 (75.0%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">23 (47.9%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Weekly cigarette roll‐up use</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">15 (62.5%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">19 (79.2%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">34 (70.8%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">9 (37.5%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (20.8%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">14 (29.2%)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Monthly use of any other illicit drug</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">22 (91.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">22 (91.7%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">44 (91.7%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (8.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (8.3%)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (8.3%)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="add16154-ntgp-0003">
                  <fn id="add16154-note-0005">
                    <p><italic toggle="yes">Note</italic>: For continuous data, mean (SD) [minimum–maximum] is shown, for categorical data, <italic toggle="yes">n</italic> (%) is shown.</p>
                  </fn>
                  <fn id="add16154-note-0006">
                    <p>Abbreviations = AUDIT, Alcohol Use Disorders Identification Test; BDI = Beck Depression Inventory; CUDIT‐R = Cannabis Use disorder Identification Test‐Revised; SES = socio‐economic status; s‐UPPS‐P = Short Urgency‐Premeditation‐Perseverance‐Sensation Seeking‐Positive Urgency.</p>
                  </fn>
                  <fn id="add16154-note-0007">
                    <label>*</label>
                    <p><italic toggle="yes">P</italic> &lt; 0.05.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Pre‐drug administration (T1) minimal THC was detected in plasma. Across the three conditions, four participants had a plasma THC level &gt;0.5 ng/mL; all other participants had plasma THC levels that were zero. The non‐zero levels were all &lt;1.25 ng/mL. Pre‐drug administration, at T1, across the three conditions, all participants had a zero plasma CBD level (Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S17a</xref>).</p>
              <sec id="add16154-sec-0017">
                <title>Primary outcomes</title>
                <p>For subjective ‘feel drug effect’ (at T2, 20 min; Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S9</xref>; Figure <xref rid="add16154-fig-0001" ref-type="fig">1a,b</xref>), a Greenhouse–Geisser correction was implemented. There was no significant interaction between drug and age‐group (<italic toggle="yes">F</italic>[2,92] = 0.557; <italic toggle="yes">P</italic> = 0.547; η<sup>2</sup>
<sub>p</sub> = 0.012). There was a main effect of both drug (<italic toggle="yes">F</italic>[2,92] = 262.214; <italic toggle="yes">P</italic> &lt; 0.001; η<sup>2</sup>
<sub>p</sub> = 0.851) and age group (<italic toggle="yes">F</italic>[1,45] = 8.190; <italic toggle="yes">P</italic> = 0.006; η<sup>2</sup>
<sub>p</sub> = 0.151). ‘THC’ led to greater ratings than ‘PLA’ (mean difference [MD] = 6.292; 95% CI = 5.343–7.240; <italic toggle="yes">t</italic>(46) = 16.480; <italic toggle="yes">P</italic> &lt; 0.001), and ‘THC + CBD’ led to greater ratings than ‘PLA’ (MD = 6.813; 95% CI = 5.964–7.661; <italic toggle="yes">t</italic>(46) = 19.957; <italic toggle="yes">P</italic> &lt; 0.001); there was no significant difference between ‘THC’ and ‘THC + CBD’ (MD = 0.521; 95% CI = −0.121 to 1.163; <italic toggle="yes">t</italic>(46) =2.017; <italic toggle="yes">P</italic> = 0.149). Overall, across the three drug conditions (including ‘PLA’), adults had larger ‘feel drug effect’ ratings than adolescents (MD = 0.847; 95% CI = 0.251–1.443; <italic toggle="yes">t</italic>(45) =2.862; <italic toggle="yes">P</italic> = 0.006). However, null age‐group differences in the ‘THC minus PLA’ value were supported by Bayesian analysis (BF<sub>01</sub> = 3.591), providing evidence that adolescents and adults responded similarly. When comparing ‘THC’ and ‘THC + CBD’, Bayesian results were inconclusive (BF<sub>01</sub> = 1.328). These results did not significantly change when controlling for drug order or when removing participants with outlying subjective or plasma data.</p>
                <fig position="float" fig-type="FIGURE" id="add16154-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Mean values with data points overlaid and 95% CI displayed for primary outcomes. (a) VAS ‘feel drug effect’ at T2, (c) prose recall score (delayed) at T4 and (e) PSI total at T4, for adolescents (<italic toggle="no">n</italic> = 24) and adults (<italic toggle="no">n</italic> = 24) during ‘THC’, ‘THC + CBD’ and ‘PLA’ conditions. Main effect of drug across age groups displayed in (b), (d), and (f) where their data are combined (<italic toggle="no">n</italic> = 48). **<italic toggle="no">P</italic> &lt; 0.01, ***<italic toggle="no">P</italic> &lt; 0.001. PSI = psychotomimetic states inventory; VAS = visual analogue scale; THC = delta‐9‐tetrahydocannabinol; CBD = cannabidiol; PLA = placebo.</p>
                  </caption>
                  <graphic xlink:href="ADD-118-1282-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>For prose recall delayed scores (Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S9</xref> and Figure <xref rid="add16154-fig-0001" ref-type="fig">1c,d</xref>), there was no significant interaction between drug and age group (<italic toggle="yes">F</italic>[2,92] = 0.727; <italic toggle="yes">P</italic> = 0.486; η<sup>2</sup>
<sub>p</sub> = 0.016). There was a main effect of drug (<italic toggle="yes">F</italic>[2,92] = 20.616; <italic toggle="yes">P</italic> &lt; 0.001; η<sup>2</sup>
<sub>p</sub> = 0.309), but not of age group (<italic toggle="yes">F</italic>[1,45] = 0.073; <italic toggle="yes">P</italic> = 0.789; η<sup>2</sup>
<sub>p</sub> = 0.002). ‘THC’ led to lower (delayed) prose recall scores than ‘PLA’ (MD = −2.740; 95% CI = −4.059 to −1.420; <italic toggle="yes">t</italic>(46) = 5.158; <italic toggle="yes">P</italic> &lt; 0.001). ‘THC + CBD’ also led to lower scores than ‘PLA’ (MD = −2.896; 95% CI = −4.130 to −1.662; <italic toggle="yes">t</italic>(46) = 5.830; <italic toggle="yes">P</italic> &lt; 0.001). Furthermore, there was no significant difference between scores during ‘THC’ and ‘THC + CBD’ (MD = 0.156; 95% CI = −1.069 to 1.381; <italic toggle="yes">t</italic>(46) = 0.317; <italic toggle="yes">P</italic> = 1.00). Null age‐group differences in ‘THC minus PLA’ were supported by Bayesian analysis (BF<sub>01</sub> = 3.192), providing evidence that adolescents and adults responded similarly. Additionally, Bayesian analysis provided evidence that CBD did not impact THC effects on prose recall (BF<sub>01</sub> = 8.423). These results did not significantly change when controlling for drug order or when removing participants with outlying subjective or plasma data.</p>
                <p>For psychotomimetic effects (PSI total score; Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S9</xref>, Figure <xref rid="add16154-fig-0001" ref-type="fig">1e,f</xref>), there was no significant interaction between drug and age group (<italic toggle="yes">F</italic>[2,92] = 0.932; <italic toggle="yes">P</italic> = 0.398; η<sup>2</sup>
<sub>p</sub> = 0.020). There was a main effect of drug (<italic toggle="yes">F</italic>[2,92] = 18.796; <italic toggle="yes">P</italic> &lt; 0.001; η<sup>2</sup>
<sub>p</sub> = 0.290), but not of age‐group (<italic toggle="yes">F</italic>[1,45] = 1.582; <italic toggle="yes">P</italic> = 0.215; η<sup>2</sup>
<sub>p</sub> = 0.033). Across age group, ‘THC’ led to greater PSI ratings than ‘PLA’ (MD = 7.771; 95% CI = 2.844–12.698; <italic toggle="yes">t</italic>(46) = 3.919; <italic toggle="yes">P</italic> = 0.001), and ‘THC + CBD’ led to greater ratings than ‘PLA’ (MD = 10.792; 95% CI = 6.172–15.411; <italic toggle="yes">t</italic>(46) = 5.805; <italic toggle="yes">P</italic> &lt; 0.001); there was no significant difference between ‘THC’ and ‘THC + CBD’ (MD = –3.021; 95% CI = −6.954 to 0.912; <italic toggle="yes">t</italic>(46) =1.908; <italic toggle="yes">P</italic> = 0.188). Null age‐group differences for PSI ratings in ‘THC minus PLA’ were supported by Bayesian analysis (BF<sub>01</sub> = 4.385), providing evidence that adolescents and adults responded similarly. When comparing ‘THC’ and ‘THC + CBD’, Bayesian results were inconclusive (BF<sub>01</sub> = 1.589). These results did not significantly change when controlling for drug order or when removing participants with outlying subjective or plasma results.</p>
              </sec>
              <sec id="add16154-sec-0018">
                <title>Secondary outcomes</title>
                <p>Across secondary outcomes, the results generally followed a similar pattern (see Table <xref rid="add16154-tbl-0003" ref-type="table">3</xref> for summary) such that there were typically no drug by age‐group interactions and there were main effects of drug. Post hoc pairwise drug comparisons generally showed significant differences between ‘PLA’ compared with ‘THC’ and ‘THC + CBD’ and occasionally differences between outcomes during ‘THC’ and ‘THC + CBD’.</p>
                <table-wrap position="float" id="add16154-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Summary of key results for primary and secondary outcome variables</p>
                  </caption>
                  <table frame="hsides" rules="cols">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Outcome</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Drug*age‐group interaction</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Main effect of drug</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">‘THC’ &gt; ‘PLA’</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">‘THC + CBD’ &gt; ‘THC’</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td colspan="5" align="left" valign="top" rowspan="1">Primary</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Feel drug effect (T2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prose recall delayed</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PSI total</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td colspan="5" align="left" valign="top" rowspan="1">Secondary</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Subjective measures (VAS)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Feel drug effect (T2–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Like drug effect (T2–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Dislike drug effect (T2–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Anxious (T1–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Paranoid (T1–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Want cannabis (T1–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Happy (T1–T5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y<xref rid="add16154-note-0009" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prose recall</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Prose recall immediate</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PSI subscales</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Delusory thinking</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Perceptual distortion</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">‐</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Cognitive disorganisation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Anhedonia</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Mania</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Paranoia</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PANSS subscales</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">PANSS positive</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">PANSS negative</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Plasma and heart rate</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">THC plasma concentration (T2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">CBD plasma concentration (T2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y<xref rid="add16154-note-0010" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Heart rate (T2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Y</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="add16154-ntgp-0004">
                    <fn id="add16154-note-0008">
                      <p><italic toggle="yes">Note</italic>: Significant results (<italic toggle="yes">P</italic> &lt; 0.05) are denoted ‘Y’ and non‐significant results are denoted ‘<bold>–</bold>’.</p>
                      <p>Abbreviations: CBD = cannabidiol; PANSS = Positive and Negative Syndrome Scale; PLA = placebo; PSI = Psychotomimetic States Inventory; THC = delta‐9‐tetrahydocannabinol; VAS = visual analogue scale.</p>
                    </fn>
                    <fn id="add16154-note-0009">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>For ‘Happy’, adults had higher ratings than adolescents on ‘PLA’, but similar ratings on ‘THC’ and ‘THC + CBD’. Moreover, within adolescents, ratings during ‘THC’ and ‘THC + CBD’ were higher than ‘PLA’, but within adults ratings during ‘THC’ and ‘THC + CBD’ were lower than during ‘PLA’.</p>
                    </fn>
                    <fn id="add16154-note-0010">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>For CBD plasma levels, this interaction was driven by higher CBD levels on ‘THC + CBD’ in adults compared to adolescents, but similar levels in adults and adolescents during ‘PLA’ or ‘THC’.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Exceptions to this pattern included the following results. There were drug by age‐group interactions for ‘happy’ (across T1–T5; Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S5g‐i</xref>) and CBD plasma levels (T2; Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S7</xref> and Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S17b</xref>). There were significant differences between active drug conditions (‘THC + CBD’ &gt; ‘THC’) for: ‘feel drug effect’ (across T2–T5; Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S4a–c</xref>), PSI subscale cognitive disorganisation (Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S14</xref>), heart rate (Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S7e,f</xref>) and THC and CBD plasma levels (at T2) (Figure <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S7a–d</xref>; Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S17b</xref>). Notably, T2 plasma THC levels were lower on ‘THC’ (14.88 ng/mL; SD = 7.15) than ‘THC + CBD’ (27.86 ng/mL; SD = 14.20) (<italic toggle="yes">t</italic>(90.514) = 7.760, <italic toggle="yes">P</italic> &lt; 0.001).</p>
                <p>For subjective effects over time, there was no drug by age group‐by‐time interactions for any secondary outcome (Tables <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S10 and 11</xref>). For peak subjective effects and area‐under‐the‐curve data, there were no drug by age‐group interactions, and the pattern of results was mainly consistent with the previous analyses. Detailed results for all secondary outcomes are presented in the <xref rid="add16154-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="add16154-sec-0019">
              <title>DISCUSSION</title>
              <p>We carried out the first controlled experiment testing the acute effects of vaporised cannabis with and without cannabidiol in both adolescents and adults. On our three primary outcomes, subjective ‘feel drug effect’, verbal episodic memory and psychotomimetic effect, we found no evidence that age group moderated the impact of cannabis. Furthermore, Bayesian analyses supported these null results. Additionally, we found no evidence that vaporised CBD (24 mg for a 75 kg person) modulated the acute impact of vaporised THC (8 mg for a 75 kg person) on our primary outcome variables. Our results were supported by analysis of our secondary outcome variables, which showed, almost unanimously, that there were null moderating effects of age group and CBD. The mostly consistent pattern of results was (i) ‘THC’ and ‘THC + CBD’ produced expected changes from ‘PLA’; (ii) ‘THC’ and ‘THC + CBD’ did not differ from one another; and (iii) the impact of cannabis did not differ in adolescents and adults.</p>
              <p>Based on Mokrysz <italic toggle="yes">et al</italic>. [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>], we hypothesised that adolescents would be more resilient to the acute effects of cannabis than adults. We did not find evidence for this; indeed, our Bayesian analyses supported equivalence of the impact of cannabis on adolescents and adults in all three of our primary outcome variables. This partially supports Murray <italic toggle="yes">et al</italic>. [<xref rid="add16154-bib-0039" ref-type="bibr">39</xref>], which reported no differences in the impact of oral THC (fixed, 7.5 and 15 mg doses) on 18‐ to 20‐year‐olds and 30‐ to 40‐year‐olds on all subjective effects recorded, cardiovascular measures, working memory and response inhibition. In comparison to Mokrysz <italic toggle="yes">et al</italic>. [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>], in which adolescents used cannabis significantly more frequently (median, 2.4 days/week) than adults (median, 1.8 days/week), our adolescent and adult participants were matched on cannabis use frequency. The discrepancy in our findings may have been partially due to the greater frequency of cannabis use in the adolescent group in the previous experiment, therefore, contributing to a higher tolerance to THC's effects [<xref rid="add16154-bib-0057" ref-type="bibr">57</xref>]. Furthermore, in the experiment conducted by Mokrysz <italic toggle="yes">et al</italic>. [<xref rid="add16154-bib-0038" ref-type="bibr">38</xref>], adolescents weighed significantly less and received an absolutely lower dose of THC than adults.</p>
              <p>On our primary outcome variables, CBD did not significantly moderate the acute effects of THC. This is in line with previous controlled cannabis vaporisation experiments [<xref rid="add16154-bib-0034" ref-type="bibr">34</xref>, <xref rid="add16154-bib-0037" ref-type="bibr">37</xref>, <xref rid="add16154-bib-0058" ref-type="bibr">58</xref>]. Significant modulation of THC's acute effects may require pre‐dosing with larger oral [<xref rid="add16154-bib-0036" ref-type="bibr">36</xref>] or intravenous [<xref rid="add16154-bib-0035" ref-type="bibr">35</xref>] CBD. Additionally, stronger THC‐induced psychotomimetic effects may be necessary before the protective effect of CBD is observed [<xref rid="add16154-bib-0059" ref-type="bibr">59</xref>].</p>
              <p>However, there were some notable exceptions to the primarily null findings. First, there was some limited evidence that ‘THC + CBD’ produced stronger effects than ‘THC’: ‘feel drug effect’ was half a point greater on ‘THC + CBD’ compared to ‘THC’, when collapsing across all timepoints, and this was supported by an area‐under‐the‐curve difference too; the PSI cognitive disorganisation subscale was greater by ~2 points on ‘THC + CBD’ compared to ‘THC’; and heart rate was greater on ‘THC + CBD’ than ‘THC’ by 8 beats/min. To contextualise these differences, the ‘THC’ versus ‘PLA’ conditions gave differences of 4.5 points, 4 points and 18 beats/min, respectively. Notably, these were secondary outcome variables. They should also be considered against a backdrop of null CBD moderation effects on ‘like drug’, ‘dislike drug’, ‘paranoid’, ‘want cannabis’, all other PSI subscales, prose recall performance and both positive and negative PANSS scores. The supplementary analyses of area‐under‐the‐curve and peak subjective effects (<xref rid="add16154-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>, Section 3.5.2) confirmed there was no significant moderation by CBD, apart from on ‘feel drug effect’. On the whole, CBD did not appear to moderate THC's acute effects.</p>
              <p>Mean THC plasma concentrations at T2 for ‘THC’ (15 ng/mL) and ‘THC + CBD’ (28 ng/mL) conditions (Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S17b</xref>) are in line with some previous THC vaporisation studies [<xref rid="add16154-bib-0060" ref-type="bibr">60</xref>, <xref rid="add16154-bib-0061" ref-type="bibr">61</xref>], but slightly lower than other studies [<xref rid="add16154-bib-0062" ref-type="bibr">62</xref>, <xref rid="add16154-bib-0063" ref-type="bibr">63</xref>]. Mean plasma CBD concentration at T2 for the ‘THC + CBD’ condition was 55 ng/mL, with zero or trace levels in the ‘THC’ condition. Some [<xref rid="add16154-bib-0061" ref-type="bibr">61</xref>, <xref rid="add16154-bib-0063" ref-type="bibr">63</xref>, <xref rid="add16154-bib-0064" ref-type="bibr">64</xref>], but not all [<xref rid="add16154-bib-0060" ref-type="bibr">60</xref>, <xref rid="add16154-bib-0065" ref-type="bibr">65</xref>], previous research has reported that CBD co‐administration enhances THC plasma levels. It is unclear why THC levels were greater under the ‘THC + CBD’ condition relative to the ‘THC’ condition. A pharmacokinetic explanation, whereby CBD augments THC levels by inhibiting the metabolism of THC [<xref rid="add16154-bib-0066" ref-type="bibr">66</xref>], is possible. However, another possible explanation is the difference in inhalation time. Participants took significantly longer to inhale the ‘THC + CBD’ vapour and coughed significantly more during ‘THC + CBD’ compared with ‘THC’. Our supplementary analysis (Table <xref rid="add16154-supitem-0001" ref-type="supplementary-material">S21</xref>) demonstrated that those who took longer to complete the second balloon had higher plasma THC levels at T2, therefore, partially explaining the impact of CBD on plasma THC levels. Future, detailed analyses of our pharmacokinetic data may shed light on this, but this is beyond the scope of the current manuscript. Despite the greater plasma THC levels in the ‘THC + CBD’ condition, we did not observe stronger effects on our primary outcome variables. Speculatively, this could be because CBD pharmacokinetically increases THC levels, but partially pharmacodynamically blocks THC's effects. Alternatively, there may not be a simple linear relationship between plasma THC levels and subjective, psychological effects [<xref rid="add16154-bib-0067" ref-type="bibr">67</xref>, <xref rid="add16154-bib-0068" ref-type="bibr">68</xref>, <xref rid="add16154-bib-0069" ref-type="bibr">69</xref>]. Additional research into the pharmacokinetics of co‐administered THC and CBD is required.</p>
              <p>We also detected an age‐group by drug interaction for CBD plasma level, in which adults had greater CBD levels than adolescents (<italic toggle="yes">P</italic> &lt; 0.001; MD = 21 ng/mL). Adults weighed slightly more than the adolescents and therefore, received more CBD (20 mg vs 22 mg), although that difference was not statistically significant. The two age groups took similar times to inhale the balloons. The variance in CBD plasma levels was much greater in adults than adolescents, with many adults surpassing 100 ng/mL, but no adolescents surpassing 80 ng/mL. The reason for this difference is unknown. This age difference in CBD absorption appears not to have meaningfully altered our psychological outcomes. We only found one significant drug by age‐group interaction, on ‘happy’. This unhypothesised interaction was driven by adults being slightly happier on placebo than active drug, whereas adolescents were slightly happier on active drugs than on placebo.</p>
              <p>Our study has numerous strengths. In addition to its novelty, we biochemically verified drug abstinence; we improved on previous work by matching adolescent and adult users on cannabis use; including equal numbers of men and women; and we powered our study to detect an age‐group by drug interaction and took account of winner's curse [<xref rid="add16154-bib-0055" ref-type="bibr">55</xref>]. One limitation is the absence of a CBD‐only condition. A further limitation is that our results may not generalise beyond adolescents ages 16 to 17 years and adults ages 26 to 29 years, who use cannabis 0.5–3 days/week. It is possible that younger adolescents or older adults could respond differently to the administration of cannabis. Moreover, it is possible that some age differences may be apparent in less frequent [<xref rid="add16154-bib-0039" ref-type="bibr">39</xref>] or more frequent cannabis users.</p>
              <p>Our findings have important scientific, policy and educational implications. First, they cast doubt on the claim that adolescent cannabis users are more vulnerable to some short‐term effects of cannabis than adult cannabis users. Second, our results add further weight to the claim that doses of vaporised CBD, which are near to naturally occurring levels, do not mitigate the acute harms of THC [<xref rid="add16154-bib-0034" ref-type="bibr">34</xref>, <xref rid="add16154-bib-0061" ref-type="bibr">61</xref>]. Harm reduction messages should avoid stating that CBD found in recreational cannabis protects against the acute psychotomimetic or verbal memory‐impairing effects of cannabis.</p>
            </sec>
            <sec id="add16154-sec-0021">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Will Lawn</bold>: Conceptualisation, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, visualisation, writing—original draft and writing—review and editing. <bold>Katie Trinci</bold>: Data curation, formal analysis, investigation, project administration, validation, visualisation, writing—original draft and writing—review and editing. <bold>Claire Mokrysz</bold>: Conceptualisation, data curation, investigation, funding acquisition, methodology, project administration, supervision and writing—review and editing. <bold>Anna Borissova</bold>: Conceptualisation, formal analysis, investigation, methodology, project administration, supervision and writing—review and editing. <bold>Shelan Ofori</bold>—Investigation, project administration, writing—original draft, and writing—review and editing. <bold>Kat Petrilli</bold>: investigation, project administration, methodology, writing—original draft and writing—review and editing. <bold>Michael Bloomfield</bold>: Conceptualisation, supervision and writing—review and editing. <bold>Zarah R. Haniff</bold>: Investigation, project administration, writing—original draft and writing—review and editing. <bold>Daniel Hall</bold>: Investigation, project administration, writing—original draft and writing—review and editing. <bold>Natalia Fernandez‐Vinson</bold>: Investigation, project administration, writing—original draft and writing—review and editing. <bold>Simiao Wang</bold>: Project administration, writing—original draft and writing—review and editing. <bold>Amir Englund</bold>: Conceptualisation, methodology and writing—review and editing. <bold>Edward Chesney</bold>: Conceptualisation, methodology and writing—review and editing. <bold>Matthew B. Wall</bold>: Conceptualisation, formal analysis, investigation, methodology, project administration, supervision and writing—review and editing. <bold>Tom P. Freeman</bold>: Conceptualisation, funding acquisition, investigation, methodology, project administration, supervision, validation, visualisation, writing—original draft and writing—review and editing. <bold>H. Valerie Curran</bold>: Conceptualisation, funding acquisition, investigation, methodology, project administration, supervision, validation, visualisation, writing—original draft and writing—review and editing.</p>
            </sec>
            <sec id="add16154-sec-0023">
              <title>CLINICAL TRIAL REGISTRATION DETAILS</title>
              <p>Although not deemed to be a clinical trial by the UK Medicines and Healthcare products Regulatory Agency, given international variations in defining a clinical trial, this study was registered on <ext-link xlink:href="http://Clinical.Trials.gov" ext-link-type="uri">Clinical.Trials.gov</ext-link> (NCT04851392).</p>
            </sec>
            <sec id="add16154-sec-0024">
              <title>PROTOCOL AND ANALYSIS PRE‐REGISTRATION</title>
              <p>
                <ext-link xlink:href="https://osf.io/z638r/" ext-link-type="uri">https://osf.io/z638r/</ext-link>
              </p>
              <p>
                <ext-link xlink:href="https://osf.io/v4d5x/" ext-link-type="uri">https://osf.io/v4d5x/</ext-link>
              </p>
            </sec>
            <sec sec-type="COI-statement" id="add16154-sec-0022">
              <title>DECLARATION OF INTERESTS</title>
              <p>W.L., K.T., C.M., A.B., S.O., M.B., Z.H., D.H., N.F.V., S.W., A.E., T.P.F. and H.V.C. declare no competing interests. A.E. has received speaker's honoraria from Jazz Pharmaceuticals. M.W. is primarily employed by Invicro.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="add16154-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Figure S1.</bold> Drug administration session schedule indicating when outcome measures were assessed, where time‐inh = start of drug inhalation. Administration 1 and 2 = inhalation of first and second balloon filled with cannabis vapour (‘THC’, ‘THC + CBD’ or ‘PLA’), respectively. Relative to time‐inh: T1 = −5 min, T2 = +20 min, T3 = +30 min, T4 = +120 min and T5 = +160 min. Adm = administration, imm = immediate, del = delayed, min = minutes, VAS = visual analogue scale, PSI = psychotomimetic states inventory, MRI = magnetic resonance imaging, PANSS=Positive and Negative Syndrome scale.</p>
                  <p><bold>Figure S2.</bold> Example of subjective effects visual analogue scale (VAS) for a single response variable.</p>
                  <p><bold>Figure S3.</bold> Consolidated Standards of Reporting Trials (CONSORT) flowchart for all participants. Participants' eligibility was first assessed online and subsequently on the telephone, when we recorded reasons for ineligibility. Participants' eligibility was further checked at an in‐person or video‐call baseline session. Participants who passed screening and baseline sessions were randomly allocated a drug order. We continued the experiment until 48 participants had completed all three drug administration sessions, in a per‐protocol fashion. Participants who dropped out after one or two drug administration sessions were excluded. Other reasons for dropping out include scheduling conflicts, personal reasons, and no reason given. COVID‐related restrictions were primarily because of government restrictions in March 2020 (after which the study was paused for seven months) and January 2021.</p>
                  <p><bold>Figure S4.</bold> Mean values for subjective effect VASs (‘feel drug effect’, ‘like drug effect’, and ‘dislike drug effect’) with 95% confidence intervals over time for adolescents and adults (<italic toggle="no">n</italic> = 24 per group for full datasets) during ‘PLA’, ‘THC’ and ‘THC + CBD’ conditions. VASs ranged from 0 = ‘not at all’ to 10 = ‘extremely’. Data from the two age‐groups has been combined to show overall drug effects in c, f and i (<italic toggle="no">n</italic> = 48). Relative to the start of drug inhalation (time‐inh) the timepoints correspond as following: T2 = +20 min, T3 = +30 min, T4 = +120 min, and T5 = +160 min. Subjective effect VASs was not collected before cannabis inhalation (−5mins<italic toggle="no">).</italic> VAS = visual analogue scale. Data is missing for 1 adult during T5 of ‘THC + CBD’.</p>
                  <p><bold>Figure S5.</bold> Mean values for subjective effect VASs (‘anxious’, ‘paranoid’, ‘want cannabis’, and ‘happy’) with 95% confidence intervals over time for adolescents and adults (<italic toggle="no">n</italic> = 24 per group for full datasets) during ‘PLA’, ‘THC’ and ‘THC + CBD’ conditions. VASs ranged from 0 = ‘not at all’ to 10 = ‘extremely’. Data from the two age groups has been combined to show overall drug effects in c, f, i, and l (<italic toggle="no">n</italic> = 48). Relative to the start of drug inhalation (time‐inh) the timepoints correspond as following: T1 = −5 min, T2 = +20 min, T3 = +30 min, T4 = +120 min, and T5 = +160 min. VAS = visual analogue scale. Data is missing for 1 adult during T5 of ‘THC + CBD’.</p>
                  <p><bold>Figure S6.</bold> PANSS positive and negative subscale score, presented as mean values with 95% confidence intervals for adolescents (<italic toggle="no">n</italic> = 24) and adults <italic toggle="no">(n</italic> = 24) during</p>
                  <p><bold>Figure S7.</bold> Mean values with 95% confidence intervals displayed with all data points for a) THC plasma levels at T2, c) CBD plasma levels at T2 and e) heart rate at T2 for adolescents and adults during ‘THC’, ‘THC + CBD’ and ‘PLA’ conditions. Main effect of drug across age‐groups displayed in b, d, and f where their data is combined. **p &lt; 0.01, ***p &lt; 0.001. Relative to the start of drug administration T2 = +20 minutes. Bpm = beats per minute.</p>
                  <p><bold>Table S1.</bold> Inclusion and exclusion criteria for all participants, where criteria only relate to specific group (e.g. adolescent/adult/female/male) this is stated within the table.</p>
                  <p><bold>Table S2.</bold> Number of participants with missing data for all variables <italic toggle="no">(n).</italic>
</p>
                  <p><bold>Table S3.</bold> Number of extreme outliers for all outcome.</p>
                  <p><bold>Table S4.</bold> Baseline and demographic data. Either <italic toggle="no">n</italic> (%) or mean (SD) [min‐max].</p>
                  <p><bold>Table S5.</bold> Cannabis use information. Either <italic toggle="no">n</italic> (%) or mean (SD) [min‐max].</p>
                  <p><bold>Table S6.</bold> Lifetime drug use variables. <italic toggle="no">N</italic> (%).</p>
                  <p><bold>Table S7.</bold> Sociodemographic and cannabis use information of participant<bold>s</bold> who dropped‐out, compared with participants who were included. Either n (%) or mean (SD).</p>
                  <p><bold>Table S8.</bold> Time since last cannabis use (hours) before each session. Mean (SD) [min – max].</p>
                  <p><bold>Table S9.</bold> Descriptive statistics of primary outcomes.</p>
                  <p><bold>Table S10a‐g.</bold> Results from 2x3x4 and 2x3x5 mixed ANOVA analyses of subjective effect VASs, showing main effects and interactions. Where each analysis had a within subject factors of drug (‘PLA’, ‘THC’, and ‘THC + CBD’) and time (T1‐T5, or T2‐T5*) and a between subject factor of age‐group (adolescent, <italic toggle="no">n</italic> = 24; and adult <italic toggle="no">n</italic> = 24). ‘Feel drug effect’, ‘like drug effect’ and ‘dislike drug effect’ were completed T2‐T5; ‘anxious’, ‘paranoid’, ‘want cannabis’ and ‘happy' were completed T1‐T5.</p>
                  <p><bold>Table S11.</bold> Prose recall immediate and delayed 2x2x3 mixed ANOVA, with within subject factors of time (immediate and delayed*) and drug (‘PLA’, ‘THC’, and ‘THC + CBD’), and a between subject factor of age‐group (adolescent, <italic toggle="no">n</italic> = 24; and adult <italic toggle="no">n</italic> = 24).</p>
                  <p><bold>Table S12.</bold> PSI subscale scores for adolescents (<italic toggle="no">n</italic> = 24), adults (<italic toggle="no">n</italic> = 24), and both (<italic toggle="no">n</italic> = 48) across each drug session. Mean (SD), [median, min‐max].</p>
                  <p><bold>Table S13.</bold> Two‐way mixed ANOVA results for PSI subscale scores with a within subjects factor of drug (‘PLA’, ‘THC’, and ‘THC + CBD’) and a between subjects factor of age‐group (adolescent, <italic toggle="no">n</italic> = 24; and adult <italic toggle="no">n</italic> = 24).</p>
                  <p><bold>Table S14.</bold> Pairwise comparisons (following mixed‐ANOVA) of each PSI subscale scores between drug conditions following a main effect of drug.</p>
                  <p><bold>Table S15.</bold> Descriptive Statistics for PANSS Positive and Negative subscale scores across each drug condition for adolescents (<italic toggle="no">n</italic> = 24) and adults (<italic toggle="no">n</italic> = 24), mean (SD) [median, min‐max].</p>
                  <p><bold>Table S16.</bold> Clinically significant psychotic reaction on PANSS positive and negative (i.e. score &gt;3 greater than minimum) for adolescents (<italic toggle="no">n</italic> = 24) and adults (<italic toggle="no">n</italic> = 24). <italic toggle="no">n</italic> (%) is shown.</p>
                  <p>‘THC’, ‘THC + CBD’ and ‘PLA’ conditions. Main effect of drug across age‐groups displayed in ‘Both’ (b and d) graphs where participant data is combined (<italic toggle="no">n</italic> = 48). **<italic toggle="no">P</italic> &lt; 0.01, ***<italic toggle="no">P</italic> &lt; 0.001. PANSS = positive and negative syndrome scale.</p>
                  <p><bold>Table S17a.</bold> Plasma THC and CBD concentrations (ng.ml<sup>−<italic toggle="no">1</italic>
</sup>) in adolescents and adults at T1 (5 minutes before start of cannabis inhalation). Adolescent (<italic toggle="no">n</italic> = 24), adult (<italic toggle="no">n</italic> = 24) and both (<italic toggle="no">n</italic> = 48) for complete datasets. Mean (SD) [median, range].</p>
                  <p><bold>Table S17b.</bold> Plasma THC and CBD concentrations (ng.ml<sup><italic toggle="no">−</italic>1<italic toggle="no">)</italic></sup> in adolescents and adults at T2 (20 minutes after start of cannabis inhalation). Adolescent (<italic toggle="no">n</italic> = 24), adult (<italic toggle="no">n</italic> = 24) and both (<italic toggle="no">n</italic> = 48) for complete datasets. Mean (SD) [range].</p>
                  <p><bold>Table S18.</bold> Heart rate at T2 (20 minutes after beginning cannabis inhalation). Adolescent (<italic toggle="no">n</italic> = 24), adult (<italic toggle="no">n</italic> = 24) for complete datasets. Mean (SD) [min‐max].</p>
                  <p><bold>Table S19.</bold> Participants' guess regarding which drug they received at the end of each drug administration session. Adolescent (<italic toggle="no">n</italic> = 24), adult (<italic toggle="no">n</italic> = 24) for complete datasets. n(%).</p>
                  <p><bold>Table S20.</bold> Cumulative time taken (minutes) to inhale both balloons filled with cannabis vapour during each session. Adolescents (<italic toggle="no">n</italic> = 24) and adults (<italic toggle="no">n</italic> = 24) unless otherwise stated. Mean (SD), [median, min‐max].</p>
                  <p><bold>Table S21.</bold> Multilevel model results for THC plasma levels (T2)</p>
                </caption>
                <media xlink:href="ADD-118-1282-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="add16154-sec-0020">
              <title>ACKNOWLEDGEMENTS</title>
              <p>We thank all the participants who took part, Sharinjeet Dhiman for helping to coordinate the study and all the graduate students who were involved in data collection. We also thank Storz and Bickel, Germany, for providing the Volcano Medic.</p>
            </ack>
            <ref-list id="add16154-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="add16154-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="book" id="add16154-cit-0001"><collab collab-type="authors">NHS Digital</collab>
. <source>Smoking, drinking and drug use among young people in England in 2021</source>
<publisher-name>NHS Digital</publisher-name>; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="add16154-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="book" id="add16154-cit-0002"><collab collab-type="authors">NHS Digital</collab>
. <source>Smoking, drinking and drug use among young people in England in 2018</source>
<publisher-name>NHS Digital</publisher-name>; <year>2019</year>. <ext-link xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/smoking-drinking-and-drug-use-among-young-people-in-england/2018" ext-link-type="uri">https://digital.nhs.uk/data-and-information/publications/statistical/smoking-drinking-and-drug-use-among-young-people-in-england/2018</ext-link>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0003"><collab collab-type="authors">The University of Michigan</collab>
. <article-title>Monitoring the future</article-title>. National Institute on Drug Abuse. <year>2020</year>. <pub-id pub-id-type="doi">10.3389/fdgth.2020.60892</pub-id>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0004"><string-name><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>WT</given-names></string-name>, <string-name><surname>Sampson</surname><given-names>N</given-names></string-name>, <string-name><surname>Kessler</surname><given-names>RC</given-names></string-name>, <string-name><surname>Anthony</surname><given-names>JC</given-names></string-name>, <string-name><surname>Angermeyer</surname><given-names>M</given-names></string-name>, et al. <article-title>Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO world mental health surveys</article-title>. <source>PLoS Med</source>. <year>2008</year>;<volume>5</volume>(<issue>7</issue>):<elocation-id>e141</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0050141</pub-id><pub-id pub-id-type="pmid">18597549</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0005"><string-name><surname>Chen</surname><given-names>CY</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>MS</given-names></string-name>, <string-name><surname>Anthony</surname><given-names>JC</given-names></string-name>. <article-title>Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001</article-title>. <source>Drug Alcohol Depend</source>. <year>2005</year>;<volume>79</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2004.11.014</pub-id>
<pub-id pub-id-type="pmid">15943940</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0006"><string-name><surname>Volkow</surname><given-names>ND</given-names></string-name>, <string-name><surname>Han</surname><given-names>B</given-names></string-name>, <string-name><surname>Einstein</surname><given-names>EB</given-names></string-name>, <string-name><surname>Compton</surname><given-names>WM</given-names></string-name>. <article-title>Prevalence of substance use disorders by time since first substance use among young people in the US</article-title>. <source>JAMA Pediatr</source>. <year>2021</year>:<fpage>640</fpage>–<lpage>643</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.6981</pub-id>
<pub-id pub-id-type="pmid">33779715</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0007"><string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Lees</surname><given-names>R</given-names></string-name>, <string-name><surname>Trinci</surname><given-names>K</given-names></string-name>, <string-name><surname>Petrilli</surname><given-names>K</given-names></string-name>, <string-name><surname>Skumlien</surname><given-names>M</given-names></string-name>, et al. <article-title>The CannTeen study: Cannabis use disorder, depression, anxiety, and psychotic‐like symptoms in adolescent and adult cannabis users and age‐matched controls</article-title>. <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="add16154-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0008"><string-name><surname>Hall</surname><given-names>W</given-names></string-name>, <string-name><surname>Lynskey</surname><given-names>M</given-names></string-name>. <article-title>Assessing the public health impacts of legalizing recreational cannabis use: The US experience</article-title>. <source>World Psychiatry</source>. <year>2020</year>;<volume>19</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20735</pub-id>
<pub-id pub-id-type="pmid">32394566</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0009"><string-name><surname>Sarvet</surname><given-names>AL</given-names></string-name>, <string-name><surname>Wall</surname><given-names>MM</given-names></string-name>, <string-name><surname>Keyes</surname><given-names>KM</given-names></string-name>, <string-name><surname>Cerdá</surname><given-names>M</given-names></string-name>, <string-name><surname>Schulenberg</surname><given-names>JE</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>PM</given-names></string-name>, et al. <article-title>Recent rapid decrease in adolescents' perception that marijuana is harmful, but no concurrent increase in use</article-title>. <source>Drug Alcohol Depend</source>. <year>2018</year>;<volume>186</volume>:<fpage>68</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.12.041</pub-id>
<pub-id pub-id-type="pmid">29550624</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0010"><string-name><surname>Cerdá</surname><given-names>M</given-names></string-name>, <string-name><surname>Mauro</surname><given-names>C</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>A</given-names></string-name>, <string-name><surname>Levy</surname><given-names>NS</given-names></string-name>, <string-name><surname>Santaella‐Tenorio</surname><given-names>J</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>D</given-names></string-name>, et al. <article-title>Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016</article-title>. <source>JAMA Psychiat</source>. <year>2020</year>;<volume>77</volume>(<issue>2</issue>):<fpage>165</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.3254</pub-id>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0011"><string-name><surname>Wilson</surname><given-names>J</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Mackie</surname><given-names>CJ</given-names></string-name>. <article-title>Effects of increasing cannabis potency on adolescent health</article-title>. <source>Lancet Child Adolesc Health</source>. <year>2019</year>;<volume>3</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-4642(18)30342-0</pub-id>
<pub-id pub-id-type="pmid">30573419</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0012"><string-name><surname>Blakemore</surname><given-names>S</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>S</given-names></string-name>. <article-title>Development of the adolescent brain: Implications for executive function and social cognition</article-title>. <source>J Child Psychol Psychiatry</source>. <year>2006</year>;<volume>47</volume>(<issue>3–4</issue>):<fpage>296</fpage>–<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-7610.2006.01611.x</pub-id>
<pub-id pub-id-type="pmid">16492261</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0013"><string-name><surname>Dumontheil</surname><given-names>I</given-names></string-name>. <article-title>Adolescent brain development</article-title>. <source>Curr Opin Behav Sci</source>. <year>2016</year>;<volume>10</volume>:<fpage>39</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.cobeha.2016.04.012</pub-id>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0014"><string-name><surname>Giedd</surname><given-names>JN</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>J</given-names></string-name>, <string-name><surname>Jeffries</surname><given-names>NO</given-names></string-name>, <string-name><surname>Castellanos</surname><given-names>FX</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Zijdenbos</surname><given-names>A</given-names></string-name>, et al. <article-title>Brain development during childhood and adolescence: A longitudinal MRI study</article-title>. <source>Nat Neurosci</source>. <year>1999</year>;<volume>2</volume>(<issue>10</issue>):<fpage>861</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/13158</pub-id>
<pub-id pub-id-type="pmid">10491603</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0015"><string-name><surname>Shaffer</surname><given-names>DR</given-names></string-name>, <string-name><surname>Kipp</surname><given-names>K</given-names></string-name>. <article-title>Developmental psychology: Childhood and adolescence</article-title>. <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="add16154-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0016"><string-name><surname>Meyer</surname><given-names>HC</given-names></string-name>, <string-name><surname>Lee</surname><given-names>FS</given-names></string-name>, <string-name><surname>Gee</surname><given-names>DG</given-names></string-name>. <article-title>The role of the endocannabinoid system and genetic variation in adolescent brain development</article-title>. <source>Neuropsychopharmacology</source>. <year>2018</year>;<volume>43</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.143</pub-id>
<pub-id pub-id-type="pmid">28685756</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0017"><string-name><surname>Galve‐Roperh</surname><given-names>I</given-names></string-name>, <string-name><surname>Palazuelos</surname><given-names>J</given-names></string-name>, <string-name><surname>Aguado</surname><given-names>T</given-names></string-name>, <string-name><surname>Guzmán</surname><given-names>M</given-names></string-name>. <article-title>The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source>. <year>2009</year>;<volume>259</volume>(<issue>7</issue>):<fpage>371</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-009-0028-y</pub-id>
<pub-id pub-id-type="pmid">19588184</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0018"><string-name><surname>Kessler</surname><given-names>RC</given-names></string-name>, <string-name><surname>Berglund</surname><given-names>P</given-names></string-name>, <string-name><surname>Demler</surname><given-names>O</given-names></string-name>, <string-name><surname>Jin</surname><given-names>R</given-names></string-name>, <string-name><surname>Merikangas</surname><given-names>KR</given-names></string-name>, <string-name><surname>Walters</surname><given-names>EE</given-names></string-name>. <article-title>Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey Replication</article-title>. <source>Arch Gen Psychiatry</source>. <year>2005</year>;<volume>62</volume>(<issue>6</issue>):<fpage>593</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.62.6.593</pub-id>
<pub-id pub-id-type="pmid">15939837</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0019"><string-name><surname>Paus</surname><given-names>T</given-names></string-name>, <string-name><surname>Keshavan</surname><given-names>M</given-names></string-name>, <string-name><surname>Giedd</surname><given-names>JN</given-names></string-name>. <article-title>Why do many psychiatric disorders emerge during adolescence?</article-title><source>Nat Rev Neurosci</source>. <year>2008</year>;<volume>9</volume>(<issue>12</issue>):<fpage>947</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2513</pub-id>
<pub-id pub-id-type="pmid">19002191</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0020"><string-name><surname>Marconi</surname><given-names>A</given-names></string-name>, <string-name><surname>Di Forti</surname><given-names>M</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CM</given-names></string-name>, <string-name><surname>Murray</surname><given-names>RM</given-names></string-name>, <string-name><surname>Vassos</surname><given-names>E</given-names></string-name>. <article-title>Meta‐analysis of the association between the level of cannabis use and risk of psychosis</article-title>. <source>Schizophr Bull</source>. <year>2016</year>;<volume>42</volume>(<issue>5</issue>):<fpage>1262</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbw003</pub-id>
<pub-id pub-id-type="pmid">26884547</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0021"><string-name><surname>Gobbi</surname><given-names>G</given-names></string-name>, <string-name><surname>Atkin</surname><given-names>T</given-names></string-name>, <string-name><surname>Zytynski</surname><given-names>T</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Askari</surname><given-names>S</given-names></string-name>, <string-name><surname>Boruff</surname><given-names>J</given-names></string-name>, et al. <article-title>Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta‐analysis</article-title>. <source>JAMA Psychiat</source>. <year>2019</year>;<volume>76</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.4500</pub-id>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0022"><string-name><surname>Lorenzetti</surname><given-names>V</given-names></string-name>, <string-name><surname>Hoch</surname><given-names>E</given-names></string-name>, <string-name><surname>Hall</surname><given-names>W</given-names></string-name>. <article-title>Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>2020</year>;<volume>36</volume>:<fpage>169</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2020.03.012</pub-id>
<pub-id pub-id-type="pmid">32268974</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0023"><string-name><surname>Hall</surname><given-names>W</given-names></string-name>, <string-name><surname>Leung</surname><given-names>J</given-names></string-name>, <string-name><surname>Lynskey</surname><given-names>M</given-names></string-name>. <article-title>The effects of cannabis use on the development of adolescents and young adults</article-title>. <source>Ann Rev Dev Psychol</source>. <year>2020</year>;<volume>2</volume>(<issue>1</issue>):<fpage>461</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-devpsych-040320-084904</pub-id>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0024"><string-name><surname>Curran</surname><given-names>VH</given-names></string-name>, <string-name><surname>Brignell</surname><given-names>C</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>S</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>P</given-names></string-name>, <string-name><surname>Henry</surname><given-names>J</given-names></string-name>. <article-title>Cognitive and subjective dose‐response effects of acute oral Δ 9‐tetrahydrocannabinol (THC) in infrequent cannabis users</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2002</year>;<volume>164</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-002-1169-0</pub-id>
<pub-id pub-id-type="pmid">12373420</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0025"><string-name><surname>D'Souza</surname><given-names>DC</given-names></string-name>, <string-name><surname>Perry</surname><given-names>E</given-names></string-name>, <string-name><surname>MacDougall</surname><given-names>L</given-names></string-name>, <string-name><surname>Ammerman</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>T</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, et al. <article-title>The psychotomimetic effects of intravenous delta‐9‐tetrahydrocannabinol in healthy individuals: Implications for psychosis</article-title>. <source>Neuropsychopharmacology</source>. <year>2004</year>;<volume>29</volume>(<issue>8</issue>):<fpage>1558</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300496</pub-id>
<pub-id pub-id-type="pmid">15173844</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0026"><string-name><surname>D'Souza</surname><given-names>DC</given-names></string-name>, <string-name><surname>Ranganathan</surname><given-names>M</given-names></string-name>, <string-name><surname>Braley</surname><given-names>G</given-names></string-name>, <string-name><surname>Gueorguieva</surname><given-names>R</given-names></string-name>, <string-name><surname>Zimolo</surname><given-names>Z</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>T</given-names></string-name>, et al. <article-title>Blunted psychotomimetic and amnestic effects of Δ‐9‐tetrahydrocannabinol in frequent users of cannabis</article-title>. <source>Neuropsychopharmacology</source>. <year>2008</year>;<volume>33</volume>(<issue>10</issue>):<fpage>2505</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301643</pub-id>
<pub-id pub-id-type="pmid">18185500</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0027"><string-name><surname>Green</surname><given-names>BOB</given-names></string-name>, <string-name><surname>Kavanagh</surname><given-names>D</given-names></string-name>, <string-name><surname>Young</surname><given-names>R</given-names></string-name>. <article-title>Being stoned: A review of self‐reported cannabis effects</article-title>. <source>Drug Alcohol Rev</source>. <year>2003</year>;<volume>22</volume>(<issue>4</issue>):<fpage>453</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1080/09595230310001613976</pub-id>
<pub-id pub-id-type="pmid">14660135</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0028"><string-name><surname>Pertwee</surname><given-names>R</given-names></string-name>. <article-title>The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin</article-title>. <source>Br J Pharmacol</source>. <year>2008</year>;<volume>153</volume>(<issue>2</issue>):<fpage>199</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707442</pub-id>
<pub-id pub-id-type="pmid">17828291</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0029"><string-name><surname>Britch</surname><given-names>SC</given-names></string-name>, <string-name><surname>Babalonis</surname><given-names>S</given-names></string-name>, <string-name><surname>Walsh</surname><given-names>SL</given-names></string-name>. <article-title>Cannabidiol: Pharmacology and therapeutic targets</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2021</year>;<volume>238</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-020-05712-8</pub-id>
<pub-id pub-id-type="pmid">33221931</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0030"><string-name><surname>Russo</surname><given-names>EB</given-names></string-name>, <string-name><surname>Burnett</surname><given-names>A</given-names></string-name>, <string-name><surname>Hall</surname><given-names>B</given-names></string-name>, <string-name><surname>Parker</surname><given-names>KK</given-names></string-name>. <article-title>Agonistic properties of cannabidiol at 5‐HT1a receptors</article-title>. <source>Neurochem Res</source>. <year>2005</year>;<volume>30</volume>(<issue>8</issue>):<fpage>1037</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-005-6978-1</pub-id>
<pub-id pub-id-type="pmid">16258853</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0031"><string-name><surname>Laprairie</surname><given-names>RB</given-names></string-name>, <string-name><surname>Bagher</surname><given-names>AM</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>MEM</given-names></string-name>, <string-name><surname>Denovan‐Wright</surname><given-names>E</given-names></string-name>. <article-title>Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor</article-title>. <source>Br J Pharmacol</source>. <year>2015</year>;<volume>172</volume>(<issue>20</issue>):<fpage>4790</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13250</pub-id>
<pub-id pub-id-type="pmid">26218440</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0032"><string-name><surname>Freeman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Petrilli</surname><given-names>K</given-names></string-name>, <string-name><surname>Lees</surname><given-names>R</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>, et al. <article-title>How does cannabidiol (CBD) influence the acute effects of delta‐9‐tetrahydrocannabinol (THC) in humans? A systematic review</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2019</year>;<volume>107</volume>:<fpage>696</fpage>–<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.09.036</pub-id>
<pub-id pub-id-type="pmid">31580839</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0033"><string-name><surname>Englund</surname><given-names>A</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>PD</given-names></string-name>, <string-name><surname>Nottage</surname><given-names>J</given-names></string-name>, <string-name><surname>Hague</surname><given-names>D</given-names></string-name>, <string-name><surname>Kane</surname><given-names>F</given-names></string-name>, <string-name><surname>Bonaccorso</surname><given-names>S</given-names></string-name>, et al. <article-title>Cannabidiol inhibits THC‐elicited paranoid symptoms and hippocampal‐dependent memory impairment</article-title>. <source>J Psychopharmacol</source>. <year>2013</year>;<volume>27</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1177/0269881112460109</pub-id>
<pub-id pub-id-type="pmid">23042808</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0034"><string-name><surname>Morgan</surname><given-names>CJA</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, <string-name><surname>Schafer</surname><given-names>G</given-names></string-name>, <string-name><surname>Gardner</surname><given-names>C</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>. <article-title>Individual and combined effects of acute delta‐9‐tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function</article-title>. <source>Transl Psychiatry</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">29317594</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0035"><string-name><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>PD</given-names></string-name>, <string-name><surname>Fusar‐Poli</surname><given-names>P</given-names></string-name>, <string-name><surname>Martin‐Santos</surname><given-names>R</given-names></string-name>, <string-name><surname>Borgwardt</surname><given-names>S</given-names></string-name>, <string-name><surname>Winton‐Brown</surname><given-names>T</given-names></string-name>, et al. <article-title>Opposite effects of Δ‐9‐tetrahydrocannabinol and cannabidiol on human brain function and psychopathology</article-title>. <source>Neuropsychopharmacology</source>. <year>2010</year>;<volume>35</volume>(<issue>3</issue>):<fpage>764</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.184</pub-id>
<pub-id pub-id-type="pmid">19924114</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0036"><string-name><surname>Englund</surname><given-names>A</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>PD</given-names></string-name>, <string-name><surname>Nottage</surname><given-names>J</given-names></string-name>, <string-name><surname>Hague</surname><given-names>D</given-names></string-name>, <string-name><surname>Kane</surname><given-names>F</given-names></string-name>, <string-name><surname>Bonaccorso</surname><given-names>S</given-names></string-name>, et al. <article-title>Cannabidiol inhibits THC‐elicited paranoid symptoms and hippocampal‐dependent memory impairment</article-title>. <source>J Psychopharmacol</source>. <year>2013</year>;<volume>27</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1177/0269881112460109</pub-id>
<pub-id pub-id-type="pmid">23042808</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0037"><string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Shaban</surname><given-names>NDC</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Pope</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, et al. <article-title>Acute effects of cannabis on speech illusions and psychotic‐like symptoms: Two studies testing the moderating effects of cannabidiol and adolescence</article-title>. <source>Psychol Med</source>. <year>2021</year>;<volume>51</volume>(<issue>12</issue>):<fpage>2134</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291720001038</pub-id>
<pub-id pub-id-type="pmid">32340632</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0038"><string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Korkki</surname><given-names>S</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>K</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>. <article-title>Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo‐controlled study in human males</article-title>. <source>Transl Psychiatry</source>. <year>2016</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e961</fpage>–<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1038/tp.2016.225</pub-id>
<pub-id pub-id-type="pmid">27898071</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0039"><string-name><surname>Murray</surname><given-names>CH</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Lee</surname><given-names>R</given-names></string-name>, <string-name><surname>de Wit</surname><given-names>H</given-names></string-name>. <article-title>Adolescents are more sensitive than adults to acute behavioral and cognitive effects of THC</article-title>. <source>Neuropsychopharmacology</source>. <year>2022</year>;<volume>47</volume>(<issue>7</issue>):<fpage>1331</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-022-01281-w</pub-id>
<pub-id pub-id-type="pmid">35110688</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0040"><string-name><surname>Treloar Padovano</surname><given-names>H</given-names></string-name>, <string-name><surname>Miranda</surname><given-names>R</given-names><suffix>Jr</suffix></string-name>. <article-title>Subjective cannabis effects as part of a developing disorder in adolescents and emerging adults</article-title>. <source>J Abnorm Psychol</source>. <year>2018</year>;<volume>127</volume>(<issue>3</issue>):<fpage>282</fpage>. <pub-id pub-id-type="doi">10.1037/abn0000342</pub-id><pub-id pub-id-type="pmid">29672090</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0041"><string-name><surname>Schramm‐Sapyta</surname><given-names>NL</given-names></string-name>, <string-name><surname>Cha</surname><given-names>YM</given-names></string-name>, <string-name><surname>Chaudhry</surname><given-names>S</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>WA</given-names></string-name>, <string-name><surname>Swartzwelder</surname><given-names>HS</given-names></string-name>, <string-name><surname>Kuhn</surname><given-names>CM</given-names></string-name>. <article-title>Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2007</year>;<volume>191</volume>(<issue>4</issue>):<fpage>867</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-006-0676-9</pub-id>
<pub-id pub-id-type="pmid">17211649</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0042"><string-name><surname>Cha</surname><given-names>YM</given-names></string-name>, <string-name><surname>White</surname><given-names>AM</given-names></string-name>, <string-name><surname>Kuhn</surname><given-names>CM</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>WA</given-names></string-name>, <string-name><surname>Swartzwelder</surname><given-names>HS</given-names></string-name>. <article-title>Differential effects of delta9‐THC on learning in adolescent and adult rats</article-title>. <source>Pharmacol Biochem Behav</source>. <year>2006</year>;<volume>83</volume>(<issue>3</issue>):<fpage>448</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2006.03.006</pub-id>
<pub-id pub-id-type="pmid">16631921</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0043"><string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Ofori</surname><given-names>S</given-names></string-name>, <string-name><surname>Trinci</surname><given-names>K</given-names></string-name>, <string-name><surname>Borissova</surname><given-names>A</given-names></string-name>, <string-name><surname>Petrilli</surname><given-names>K</given-names></string-name>, et al. <article-title>Do adolescents and adults differ in their acute subjective, behavioural, and neural responses to cannabis, with and without cannabidiol? CannTeenA [Internet]</article-title>. OSF. 2021 [cited <year>2022</year> Jul 12]. Available from: Do adolescents and adults differ in their acute subjective, behavioural, and neural responses to cannabis, with and without cannabidiol? CannTeenA.</mixed-citation>
              </ref>
              <ref id="add16154-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0044"><string-name><surname>Heatherton</surname><given-names>TF</given-names></string-name>, <string-name><surname>Kozlowski</surname><given-names>LT</given-names></string-name>, <string-name><surname>Frecker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Rickert</surname><given-names>W</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>J</given-names></string-name>. <article-title>Measuring the heaviness of smoking: Using self‐reported time to the first cigarette of the day and number of cigarettes smoked per day</article-title>. <source>Br J Addict</source>. <year>1989</year>;<volume>84</volume>(<issue>7</issue>):<fpage>791</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.1989.tb03059.x</pub-id>
<pub-id pub-id-type="pmid">2758152</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0045"><string-name><surname>van der Pol</surname><given-names>P</given-names></string-name>, <string-name><surname>Liebregts</surname><given-names>N</given-names></string-name>, <string-name><surname>de Graaf</surname><given-names>R</given-names></string-name>, <string-name><surname>Korf</surname><given-names>DJ</given-names></string-name>, <string-name><surname>van den Brink</surname><given-names>W</given-names></string-name>, <string-name><surname>van Laar</surname><given-names>M</given-names></string-name>. <article-title>Validation of self‐reported cannabis dose and potency: An ecological study</article-title>. <source>Addiction</source>. <year>2013</year>;<volume>108</volume>(<issue>10</issue>):<fpage>1801</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/add.12226</pub-id>
<pub-id pub-id-type="pmid">23627816</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0046"><string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>CJA</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, <string-name><surname>Schafer</surname><given-names>G</given-names></string-name>, <string-name><surname>Das</surname><given-names>RK</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>. <article-title>Just say ‘know’: How do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?</article-title><source>Addiction</source>. <year>2014</year>;<volume>109</volume>(<issue>10</issue>):<fpage>1686</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/add.12634</pub-id>
<pub-id pub-id-type="pmid">24894801</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0047"><string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Lorenzetti</surname><given-names>V.</given-names></string-name><article-title>A standard THC unit for reporting of health research on cannabis and cannabinoids</article-title>. <year>2021</year>. <ext-link xlink:href="https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00355-2/fulltext" ext-link-type="uri">https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00355-2/fulltext</ext-link></mixed-citation>
              </ref>
              <ref id="add16154-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="miscellaneous" id="add16154-cit-0048"><string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Lorenzetti</surname><given-names>V.</given-names></string-name><article-title>Standard THC units: a proposal to standardize dose across all cannabis products and methods of administration</article-title>. <year>2019</year>. <ext-link xlink:href="https://onlinelibrary.wiley.com/doi/full/10.1111/add.14842?casa_token=hTI8t_g_SWwAAAAA%3Ah5BiRMDjJcgGzmQ3XoXOM76qujR-_qFuKAzPQQPD0KNIphcQ2VFIlTj0vqSZi76EFVfOpEQPQD5GkooL" ext-link-type="uri">https://onlinelibrary.wiley.com/doi/full/10.1111/add.14842?casa_token=hTI8t_g_SWwAAAAA%3Ah5BiRMDjJcgGzmQ3XoXOM76qujR‐_qFuKAzPQQPD0KNIphcQ2VFIlTj0vqSZi76EFVfOpEQPQD5GkooL</ext-link></mixed-citation>
              </ref>
              <ref id="add16154-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0049"><string-name><surname>D'souza</surname><given-names>DC</given-names></string-name>, <string-name><surname>Fridberg</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Skosnik</surname><given-names>PD</given-names></string-name>, <string-name><surname>Williams</surname><given-names>A</given-names></string-name>, <string-name><surname>Roach</surname><given-names>B</given-names></string-name>, <string-name><surname>Singh</surname><given-names>N</given-names></string-name>, et al. <article-title>Dose‐related modulation of event‐related potentials to novel and target stimuli by intravenous Δ9‐THC in humans</article-title>. <source>Neuropsychopharmacology</source>. <year>2012</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1632</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2012.8</pub-id>
<pub-id pub-id-type="pmid">22334121</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0050"><string-name><surname>Heuberger</surname><given-names>J</given-names></string-name>, <string-name><surname>Guan</surname><given-names>Z</given-names></string-name>, <string-name><surname>Oyetayo</surname><given-names>O</given-names></string-name>, <string-name><surname>Klumpers</surname><given-names>L</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>P</given-names></string-name>, <string-name><surname>Beumer</surname><given-names>T</given-names></string-name>, et al. <article-title>Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short‐ and long‐term pharmacokinetics</article-title>. <source>Clin Pharmacokinet</source>. <year>2015</year>;<volume>54</volume>(<issue>2</issue>):<fpage>209</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-014-0195-5</pub-id>
<pub-id pub-id-type="pmid">25316574</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0051"><string-name><surname>Mørland</surname><given-names>J</given-names></string-name>, <string-name><surname>Bramness</surname><given-names>JG</given-names></string-name>. <article-title>Δ9‐tetrahydrocannabinol (THC) is present in the body between smoking sessions in occasional non‐daily cannabis users</article-title>. <source>Forensic Sci Int</source>. <year>2020</year>;<volume>309</volume>:<elocation-id>110188</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2020.110188</pub-id><pub-id pub-id-type="pmid">32120192</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0052"><string-name><surname>Baddeley</surname><given-names>A</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BA</given-names></string-name>. <article-title>Prose recall and amnesia: Implications for the structure of working memory</article-title>. <source>Neuropsychologia</source>. <year>2002</year>;<volume>40</volume>(<issue>10</issue>):<fpage>1737</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/S0028-3932(01)00146-4</pub-id>
<pub-id pub-id-type="pmid">11992661</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0053"><string-name><surname>Mason</surname><given-names>OJ</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>CJM</given-names></string-name>, <string-name><surname>Stefanovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>. <article-title>The psychotomimetic states inventory (PSI): Measuring psychotic‐type experiences from ketamine and cannabis</article-title>. <source>Schizophr Res</source>. <year>2008</year>;<volume>103</volume>(<issue>1–3</issue>):<fpage>138</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2008.02.020</pub-id>
<pub-id pub-id-type="pmid">18387788</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0054"><string-name><surname>Kay</surname><given-names>SR</given-names></string-name>, <string-name><surname>Fiszbein</surname><given-names>A</given-names></string-name>, <string-name><surname>Opler</surname><given-names>LA</given-names></string-name>. <article-title>The positive and negative syndrome scale (PANSS) for schizophrenia</article-title>. <source>Schizophr Bull</source>. <year>1987</year>;<volume>13</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id>
<pub-id pub-id-type="pmid">3616518</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0055"><string-name><surname>Button</surname><given-names>KS</given-names></string-name>, <string-name><surname>Ioannidis</surname><given-names>JPA</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Nosek</surname><given-names>BA</given-names></string-name>, <string-name><surname>Flint</surname><given-names>J</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>ESJ</given-names></string-name>, et al. <article-title>Power failure: Why small sample size undermines the reliability of neuroscience</article-title>. <source>Nat Rev Neurosci</source>. <year>2013</year>;<volume>14</volume>(<issue>5</issue>):<fpage>365</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3475</pub-id>
<pub-id pub-id-type="pmid">23571845</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0056"><string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Ofori</surname><given-names>S</given-names></string-name>, <string-name><surname>Trinci</surname><given-names>K</given-names></string-name>, <string-name><surname>Haniff</surname><given-names>Z</given-names></string-name>, <string-name><surname>Hall</surname><given-names>D</given-names></string-name>, et al. <article-title>Do adolescents and adults differ in the acute subjective, psychotomimetic, and memory‐impairing effects of cannabis</article-title>. <source>Open Science Framework</source>. <year>2021</year>:<fpage>1</fpage>–<lpage>11</lpage>. <ext-link xlink:href="https://osf.io/bm873" ext-link-type="uri">https://osf.io/bm873</ext-link>
</mixed-citation>
              </ref>
              <ref id="add16154-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0057"><string-name><surname>Colizzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>. <article-title>Cannabis use and the development of tolerance: A systematic review of human evidence</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2018</year>;<volume>93</volume>:<fpage>1</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.07.014</pub-id>
<pub-id pub-id-type="pmid">30056176</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0058"><string-name><surname>Lawn</surname><given-names>W</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TP</given-names></string-name>, <string-name><surname>Pope</surname><given-names>RA</given-names></string-name>, <string-name><surname>Joye</surname><given-names>A</given-names></string-name>, <string-name><surname>Harvey</surname><given-names>L</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, et al. <article-title>Acute and chronic effects of cannabinoids on effort‐related decision‐making and reward learning: An evaluation of the cannabis ‘amotivational’ hypotheses</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2016</year>;<volume>233</volume>(<issue>19–20</issue>):<fpage>3537</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-016-4383-x</pub-id>
<pub-id pub-id-type="pmid">27585792</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0059"><string-name><surname>Freeman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Petrilli</surname><given-names>K</given-names></string-name>, <string-name><surname>Lees</surname><given-names>R</given-names></string-name>, <string-name><surname>Hindocha</surname><given-names>C</given-names></string-name>, <string-name><surname>Mokrysz</surname><given-names>C</given-names></string-name>, <string-name><surname>Curran</surname><given-names>HV</given-names></string-name>, et al. <article-title>How does cannabidiol (CBD) influence the acute effects of delta‐9‐tetrahydrocannabinol (THC) in humans? A systematic review</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2019</year>;<volume>107</volume>:<fpage>696</fpage>–<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.09.036</pub-id>
<pub-id pub-id-type="pmid">31580839</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0060"><string-name><surname>Arkell</surname><given-names>TR</given-names></string-name>, <string-name><surname>Lintzeris</surname><given-names>N</given-names></string-name>, <string-name><surname>Mills</surname><given-names>L</given-names></string-name>, <string-name><surname>Suraev</surname><given-names>A</given-names></string-name>, <string-name><surname>Arnold</surname><given-names>JC</given-names></string-name>, <string-name><surname>McGregor</surname><given-names>IS</given-names></string-name>. <article-title>Driving‐related behaviours, attitudes and perceptions among Australian medical cannabis users: Results from the CAMS 18‐19 survey</article-title>. <source>Accid Anal Prev</source>. <year>2020</year>;<volume>148</volume>:<elocation-id>105784</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.aap.2020.105784</pub-id><pub-id pub-id-type="pmid">33017729</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0061"><string-name><surname>Arkell</surname><given-names>TR</given-names></string-name>, <string-name><surname>Lintzeris</surname><given-names>N</given-names></string-name>, <string-name><surname>Kevin</surname><given-names>RC</given-names></string-name>, <string-name><surname>Ramaekers</surname><given-names>JG</given-names></string-name>, <string-name><surname>Vandrey</surname><given-names>R</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>C</given-names></string-name>, et al. <article-title>Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)‐induced impairment of driving and cognition</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2019</year>;<volume>236</volume>(<issue>9</issue>):<fpage>2713</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-019-05246-8</pub-id>
<pub-id pub-id-type="pmid">31044290</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0062"><string-name><surname>Huestis</surname><given-names>MA</given-names></string-name>. <article-title>Human cannabinoid pharmacokinetics</article-title>. <source>Chem Biodivers</source>. <year>2007</year>;<volume>4</volume>(<issue>8</issue>):<elocation-id>1770</elocation-id>. <pub-id pub-id-type="doi">10.1002/cbdv.200790152</pub-id><pub-id pub-id-type="pmid">17712819</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0063"><string-name><surname>van de Donk</surname><given-names>T</given-names></string-name>, <string-name><surname>Niesters</surname><given-names>M</given-names></string-name>, <string-name><surname>Kowal</surname><given-names>MA</given-names></string-name>, <string-name><surname>Olofsen</surname><given-names>E</given-names></string-name>, <string-name><surname>Dahan</surname><given-names>A</given-names></string-name>, <string-name><surname>van Velzen</surname><given-names>M</given-names></string-name>. <article-title>An experimental randomized study on the analgesic effects of pharmaceutical‐grade cannabis in chronic pain patients with fibromyalgia</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>4</issue>):<elocation-id>860</elocation-id>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000001464</pub-id><pub-id pub-id-type="pmid">30585986</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0064"><string-name><surname>Nadulski</surname><given-names>T</given-names></string-name>, <string-name><surname>Pragst</surname><given-names>F</given-names></string-name>, <string-name><surname>Weinberg</surname><given-names>G</given-names></string-name>, <string-name><surname>Roser</surname><given-names>P</given-names></string-name>, <string-name><surname>Schnelle</surname><given-names>M</given-names></string-name>, <string-name><surname>Fronk</surname><given-names>EM</given-names></string-name>, et al. <article-title>Randomized, double‐blind, placebo‐controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9‐tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract</article-title>. <source>Ther Drug Monit</source>. <year>2005</year>;<volume>27</volume>(<issue>6</issue>):<fpage>799</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1097/01.ftd.0000177223.19294.5c</pub-id>
<pub-id pub-id-type="pmid">16306858</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0065"><string-name><surname>Solowij</surname><given-names>N</given-names></string-name>, <string-name><surname>Broyd</surname><given-names>S</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>L</given-names></string-name>, <string-name><surname>van Hell</surname><given-names>H</given-names></string-name>, <string-name><surname>Martelozzo</surname><given-names>D</given-names></string-name>, <string-name><surname>Rueb</surname><given-names>K</given-names></string-name>, et al. <article-title>A randomised controlled trial of vaporised Δ9‐tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source>. <year>2019</year>;<volume>269</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-019-00978-2</pub-id>
<pub-id pub-id-type="pmid">30661105</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0066">
                <label>66</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0066"><string-name><surname>Hložek</surname><given-names>T</given-names></string-name>, <string-name><surname>Uttl</surname><given-names>L</given-names></string-name>, <string-name><surname>Kadeřábek</surname><given-names>L</given-names></string-name>, <string-name><surname>Balíková</surname><given-names>M</given-names></string-name>, <string-name><surname>Lhotková</surname><given-names>E</given-names></string-name>, <string-name><surname>Horsley</surname><given-names>RR</given-names></string-name>, et al. <article-title>Pharmacokinetic and behavioural profile of THC, CBD, and THC+ CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>2017</year>;<volume>27</volume>(<issue>12</issue>):<fpage>1223</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2017.10.037</pub-id>
<pub-id pub-id-type="pmid">29129557</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0067">
                <label>67</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0067"><string-name><surname>Matheson</surname><given-names>J</given-names></string-name>, <string-name><surname>Sproule</surname><given-names>B</given-names></string-name>, <string-name><surname>di Ciano</surname><given-names>P</given-names></string-name>, <string-name><surname>Fares</surname><given-names>A</given-names></string-name>, <string-name><surname>le Foll</surname><given-names>B</given-names></string-name>, <string-name><surname>Mann</surname><given-names>RE</given-names></string-name>, et al. <article-title>Sex differences in the acute effects of smoked cannabis: Evidence from a human laboratory study of young adults</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2020</year>;<volume>237</volume>(<issue>2</issue>):<fpage>305</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-019-05369-y</pub-id>
<pub-id pub-id-type="pmid">31637452</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0068">
                <label>68</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0068"><string-name><surname>Theunissen</surname><given-names>EL</given-names></string-name>, <string-name><surname>Kauert</surname><given-names>GF</given-names></string-name>, <string-name><surname>Toennes</surname><given-names>SW</given-names></string-name>, <string-name><surname>Moeller</surname><given-names>MR</given-names></string-name>, <string-name><surname>Sambeth</surname><given-names>A</given-names></string-name>, <string-name><surname>Blanchard</surname><given-names>MM</given-names></string-name>, et al. <article-title>Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2012</year>;<volume>220</volume>(<issue>2</issue>):<fpage>341</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-011-2479-x</pub-id>
<pub-id pub-id-type="pmid">21975580</pub-id></mixed-citation>
              </ref>
              <ref id="add16154-bib-0069">
                <label>69</label>
                <mixed-citation publication-type="journal" id="add16154-cit-0069"><string-name><surname>Martin‐Santos</surname><given-names>R</given-names></string-name>, <string-name><surname>Crippa</surname><given-names>JA</given-names></string-name>, <string-name><surname>Batalla</surname><given-names>A</given-names></string-name>, <string-name><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>, <string-name><surname>Atakan</surname><given-names>Z</given-names></string-name>, <string-name><surname>Borgwardt</surname><given-names>S</given-names></string-name>, et al. <article-title>Acute effects of a single, oral dose of d9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers</article-title>. <source>Curr Pharm des</source>. <year>2012</year>;<volume>18</volume>(<issue>32</issue>):<fpage>4966</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.2174/138161212802884780</pub-id>
<pub-id pub-id-type="pmid">22716148</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
